Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Prostate Cancer

  Free Subscription


Articles published in Eur Urol

Retrieve available abstracts of 533 articles:
HTML format
Text format



Single Articles


    September 2019
  1. ALCARAZ A
    Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer.
    Eur Urol. 2019 Sep 12. pii: S0302-2838(19)30683.
    PubMed     Text format    


  2. NYBERG T, Frost D, Barrowdale D, Evans DG, et al
    Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
    Eur Urol. 2019 Sep 5. pii: S0302-2838(19)30675.
    PubMed     Text format     Abstract available


  3. CULP MB, Soerjomataram I, Efstathiou JA, Bray F, et al
    Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates.
    Eur Urol. 2019 Sep 4. pii: S0302-2838(19)30619.
    PubMed     Text format     Abstract available


    August 2019
  4. DONG L, Pienta KJ
    Re: Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy of Clinically Localized, High Risk Prostate Cancer.
    Eur Urol. 2019 Aug 30. pii: S0302-2838(19)30678.
    PubMed     Text format    


  5. GORCHAKOV AA, Kulemzin SV, Kochneva GV, Taranin AV, et al
    Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Eur Urol. 2019 Aug 27. pii: S0302-2838(19)30658.
    PubMed     Text format     Abstract available


  6. DROST FH, Nieboer D, Morgan TM, Carroll PR, et al
    Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
    Eur Urol. 2019 Aug 23. pii: S0302-2838(19)30602.
    PubMed     Text format     Abstract available


  7. HOYLE AP, Ali A, James ND, Cook A, et al
    Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
    Eur Urol. 2019 Aug 22. pii: S0302-2838(19)30620.
    PubMed     Text format     Abstract available


  8. RAMNARINE VR, Kobelev M, Gibb EA, Nouri M, et al
    The evolution of long noncoding RNA acceptance in prostate cancer initiation and progression, and its clinical utility in disease management.
    Eur Urol. 2019 Aug 22. pii: S0302-2838(19)30601.
    PubMed     Text format     Abstract available


  9. KELLOKUMPU-LEHTINEN PL, Hjalm-Eriksson M, Thellenberg-Karlsson C, Astrom L, et al
    Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.
    Eur Urol. 2019 Aug 20. pii: S0302-2838(19)30654.
    PubMed     Text format     Abstract available


  10. DONZELLI A, Castelluzzo G, Giudicatti G
    Re: Jonas Hugosson, Monique J. Roobol, Marianne Mansson, et al. A 16-yr Follow-up of the European Randomized Study of Screening for Prostate Cancer. Eur Urol 2019;76:43-51: Mortality in the Age Group >/=70yr and the Case of Italy.
    Eur Urol. 2019 Aug 20. pii: S0302-2838(19)30606.
    PubMed     Text format    


  11. VAN LEENDERS GJLH, Kweldam CF, Hollemans E, Kummerlin IP, et al
    Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
    Eur Urol. 2019 Aug 19. pii: S0302-2838(19)30612.
    PubMed     Text format     Abstract available


  12. GLASER AW
    Resilience of men and the gap hypothesis of quality of life: Health utility outcome measurement in prostate cancer.
    Eur Urol. 2019 Aug 16. pii: S0302-2838(19)30607.
    PubMed     Text format    


  13. DESAI NB, Courtney K, Subramaniam RM, Cadeddu JA, et al
    Salvage Radiotherapy for Nodal Oligorecurrent Prostate Cancer: A Step Towards Predictive Criteria for Metastasis-Directed Therapy in Prostate Cancer?
    Eur Urol. 2019 Aug 14. pii: S0302-2838(19)30611.
    PubMed     Text format    


  14. KASIVISVANATHAN V, Takwoingi Y, Emberton M, Moore CM, et al
    Reply to Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti's Letter to the Editor, re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostat
    Eur Urol. 2019 Aug 7. pii: S0302-2838(19)30604.
    PubMed     Text format    


  15. MONTORSI F, Gandaglia G, Briganti A
    Re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review And Meta-analysis. Eur Urol. In press. https://doi.org/10.1
    Eur Urol. 2019 Aug 7. pii: S0302-2838(19)30603.
    PubMed     Text format    


  16. LU-YAO G, Nikita N, Keith SW, Nightingale G, et al
    Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities.
    Eur Urol. 2019 Aug 2. pii: S0302-2838(19)30585.
    PubMed     Text format     Abstract available


    July 2019
  17. THOMAS L, Baratchian M, Sharifi N
    Supraphysiologic Testosterone Solutions for Enzalutamide-resistant Prostate Cancer.
    Eur Urol. 2019 Jul 31. pii: S0302-2838(19)30596.
    PubMed     Text format    


  18. VAN DER POEL H
    Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial.
    Eur Urol. 2019 Jul 26. pii: S0302-2838(19)30545.
    PubMed     Text format    


  19. BUTCHER G, Howard H, Sathianathen N, Catto JWF, et al
    Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer.
    Eur Urol. 2019 Jul 25. pii: S0302-2838(19)30542.
    PubMed     Text format    


  20. MCLENNAN D, Sathianathen N, Alghazo O, Azad A, et al
    Re: PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Jul 25. pii: S0302-2838(19)30550.
    PubMed     Text format    


  21. HOFMAN MS, Emmett L
    Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength?
    Eur Urol. 2019 Jul 24. pii: S0302-2838(19)30584.
    PubMed     Text format    


  22. SIGHINOLFI MC, Rocco B
    Re: EAU Guidelines: Prostate Cancer 2019.
    Eur Urol. 2019 Jul 23. pii: S0302-2838(19)30538.
    PubMed     Text format    


  23. STENZL A
    Re: Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Jul 23. pii: S0302-2838(19)30549.
    PubMed     Text format    


  24. JEONG CW, Cowan JE, Broering JM, Ten Ham RMT, et al
    Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry.
    Eur Urol. 2019 Jul 22. pii: S0302-2838(19)30536.
    PubMed     Text format     Abstract available


  25. WALSH PC
    Re: Association of Treatment with 5alpha-Reductase inhibitors with Time to Diagnosis and Mortality in Prostate Cancer.
    Eur Urol. 2019 Jul 22. pii: S0302-2838(19)30546.
    PubMed     Text format    


  26. DE BLESER E, Jereczek-Fossa BA, Pasquier D, Zilli T, et al
    Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
    Eur Urol. 2019 Jul 19. pii: S0302-2838(19)30533.
    PubMed     Text format     Abstract available


  27. CHEN S, Xiao Y, Wang X
    Re: Brandon A. Mahal, Mohammed Alshalalfa, Daniel E. Spratt, et al. Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores. Eur Urol 2019;75:1038-40.
    Eur Urol. 2019 Jul 17. pii: S0302-2838(19)30529.
    PubMed     Text format    


  28. DROST FH, Osses D, Nieboer D, Bangma CH, et al
    Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis.
    Eur Urol. 2019 Jul 17. pii: S0302-2838(19)30513.
    PubMed     Text format     Abstract available


  29. HACKMAN G, Taari K, Tammela TL, Matikainen M, et al
    Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension.
    Eur Urol. 2019 Jul 17. pii: S0302-2838(19)30525.
    PubMed     Text format     Abstract available


  30. PASCHALIS A, Sheehan B, Riisnaes R, Rodrigues DN, et al
    Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
    Eur Urol. 2019 Jul 13. pii: S0302-2838(19)30520.
    PubMed     Text format     Abstract available


  31. LOGOTHETIS CJ, Aparicio A, Koinis F, Corn PG, et al
    Prostate Cancer: Quo Vadis?
    Eur Urol. 2019 Jul 9. pii: S0302-2838(19)30521.
    PubMed     Text format     Abstract available


  32. PAL SK, Swami U, Agarwal N
    Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How.
    Eur Urol. 2019 Jul 9. pii: S0302-2838(19)30519.
    PubMed     Text format    


  33. DE BRUYCKER A, Fonteyne V, Ost P
    Re: Gaetan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.04.016.
    Eur Urol. 2019 Jul 9. pii: S0302-2838(19)30523.
    PubMed     Text format    


  34. VON EYBEN FE, Bauman G
    Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019:75:285-93.
    Eur Urol. 2019 Jul 9. pii: S0302-2838(19)30516.
    PubMed     Text format    


  35. DIRIX PR, Dal Pra A, Wiegel T
    Re: Gaetan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.04.016.
    Eur Urol. 2019 Jul 9. pii: S0302-2838(19)30524.
    PubMed     Text format    


    June 2019
  36. HOLSCHER T, Lohaus F, Wirth M, Troost EGC, et al
    Reply to Piet R. Dirix, Carole Mercier, and Luc Y. Dirix's Letter to the Editor re: Fabian Lohaus, Klaus Zophel, Steffen Lock, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol
    Eur Urol. 2019 Jun 27. pii: S0302-2838(19)30506.
    PubMed     Text format    


  37. DIRIX PR, Mercier C, Dirix LY
    Re: Fabian Lohaus, Klaus Zophel, Steffen Lock, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548-51.
    Eur Urol. 2019 Jun 26. pii: S0302-2838(19)30507.
    PubMed     Text format    


  38. LIN X, Helfand BT, Xu J
    Re: Daniel A. Leongamornlert, Edward J. Saunders, Sarah Wakerell, et al., Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. Eur Urol. In press. https://doi.org/10.1016/j.eur
    Eur Urol. 2019 Jun 24. pii: S0302-2838(19)30492.
    PubMed     Text format    


  39. WEI Y, Wu J, Gu W, Qin X, et al
    Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients.
    Eur Urol. 2019 Jun 24. pii: S0302-2838(19)30453.
    PubMed     Text format     Abstract available


  40. RANASINGHE WKB, Reichard CA, Chapin BF
    Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.
    Eur Urol. 2019 Jun 24. pii: S0302-2838(19)30499.
    PubMed     Text format     Abstract available


  41. KOTE-JARAI Z, Leongamornlert DA, Saunders EJ, Conti DV, et al
    Reply to Xiaoling Lin, Brian T. Helfand, and Jianfeng Xu's Letter to the Editor re: Daniel A. Leongamornlert, Edward J. Saunders, Sarah Wakerell, et al. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a
    Eur Urol. 2019 Jun 21. pii: S0302-2838(19)30491.
    PubMed     Text format    


  42. QIAN K, Ju L, Xiao Y
    Re: Stacy Loeb, Jacob Taylor, Mohit Butaney, et al. Twitter-based Prostate Cancer Journal Club (#ProstateJC) Promotes Multidisciplinary Global Scientific Discussion and Research Dissemination. Eur Urol 2019;75:881-2.
    Eur Urol. 2019 Jun 19. pii: S0302-2838(19)30454.
    PubMed     Text format    


  43. LAM HM, Nguyen HM, Labrecque MP, Brown LG, et al
    Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts.
    Eur Urol. 2019 Jun 18. pii: S0302-2838(19)30449.
    PubMed     Text format     Abstract available


  44. CLARKE N, Payne H, van der Meulen J
    Re: David W. Donnelly, Anna Gavin, Amy Downing, et al. Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.04.018.
    Eur Urol. 2019 Jun 15. pii: S0302-2838(19)30450.
    PubMed     Text format    


  45. MONTIRONI R, Cheng L, Scarpelli M, Cimadamore A, et al
    Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream?
    Eur Urol. 2019 Jun 5. pii: S0302-2838(19)30442.
    PubMed     Text format    


  46. ISAACSSON VELHO P, Fu W, Wang H, Mirkheshti N, et al
    Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Jun 5. pii: S0302-2838(19)30439.
    PubMed     Text format     Abstract available


  47. EFSTATHIOU E, Davis JW, Pisters L, Li W, et al
    Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone.
    Eur Urol. 2019 Jun 5. pii: S0302-2838(19)30414.
    PubMed     Text format     Abstract available


  48. BERG S, Cole A, Trinh QD
    Reply to Michael Froehner and Christian Thomas's Letter to the Editor re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in P
    Eur Urol. 2019 Jun 4. pii: S0302-2838(19)30447.
    PubMed     Text format    


  49. WYATT AW, Chi KN, Gleave ME
    Reply to Rodolfo Montironi, Liang Cheng, Marina Scarpelli, Alessia Cimadamore, Francesco Montorsi, and Antonio Lopez-Beltran's Letter to the Editor re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and P
    Eur Urol. 2019 Jun 2. pii: S0302-2838(19)30443.
    PubMed     Text format    


  50. VAN DER LEEST M, Israel B, Cornel EB, Zamecnik P, et al
    High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naive Men: The Next Step in Magnetic Resonance Imaging Accessibility.
    Eur Urol. 2019 Jun 2. pii: S0302-2838(19)30436.
    PubMed     Text format     Abstract available


  51. GUL ZG, Martini A, Olsson CA
    Re: Jacob A. Burns, Adam B. Weiner, William J. Catalone, et al. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol 2019;75:846-52.
    Eur Urol. 2019 Jun 1. pii: S0302-2838(19)30433.
    PubMed     Text format    


    May 2019
  52. SHAH TT, Peters M, Arya M, Ahmed HU, et al
    Reply to Zhipeng Mai's Letter to the Editor re: Taimur T. Shah, Max Peters, David Eldred-Evans, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre
    Eur Urol. 2019 May 29. pii: S0302-2838(19)30427.
    PubMed     Text format    


  53. MAI Z
    Re: Taimur T. Shah, Max Peters, David Eldred-Evans, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol. In press. https://doi.o
    Eur Urol. 2019 May 29. pii: S0302-2838(19)30428.
    PubMed     Text format    


  54. ROCCO B, Sighinolfi MC
    Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:285-93.
    Eur Urol. 2019 May 29. pii: S0302-2838(19)30437.
    PubMed     Text format    


  55. BURNS JA, Weiner AB, Kundu S
    Reply to Zeynep G. Gul, Alberto Martini, and Carl A. Olsson's Letter to the Editor re: Jacob A. Burns, Adam B. Weiner, William J. Catalona, et al. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol 2019;75:846-52.
    Eur Urol. 2019 May 28. pii: S0302-2838(19)30434.
    PubMed     Text format    


  56. AHMADZADEHFAR H, Essler M
    Reply to Bingzhi Wang, Huan Deng, and Lan Cao's Letter to the Editor re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi
    Eur Urol. 2019 May 28. pii: S0302-2838(19)30435.
    PubMed     Text format    


  57. KOSCHEL SG, Wong LM, Heinze S, Zargar H, et al
    Re: Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.
    Eur Urol. 2019 May 27. pii: S0302-2838(19)30424.
    PubMed     Text format    


  58. KASIVISVANATHAN V, Stabile A, Neves JB, Giganti F, et al
    Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2019 May 23. pii: S0302-2838(19)30360.
    PubMed     Text format     Abstract available


  59. HADASCHIK B, Ost P
    Re: Assessment of (68)Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
    Eur Urol. 2019 May 23. pii: S0302-2838(19)30420.
    PubMed     Text format    


  60. FROEHNER M, Thomas C
    Re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol 2019;75:552
    Eur Urol. 2019 May 23. pii: S0302-2838(19)30419.
    PubMed     Text format    


  61. COOPERBERG MR, Carroll PR, Dall'Era MA, Davies BJ, et al
    The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement.
    Eur Urol. 2019 May 23. pii: S0302-2838(19)30417.
    PubMed     Text format     Abstract available


  62. WANG B, Deng H, Cao L
    Re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.028.
    Eur Urol. 2019 May 17. pii: S0302-2838(19)30377.
    PubMed     Text format    


  63. ALGHAZO O, Thangasamy I, Sathianathen N, Murphy DG, et al
    Re: Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2019 May 14. pii: S0302-2838(19)30342.
    PubMed     Text format    


  64. GANDAGLIA G, Albers P, Abrahamsson PA, Briganti A, et al
    Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
    Eur Urol. 2019 May 12. pii: S0302-2838(19)30347.
    PubMed     Text format     Abstract available


  65. LIANG J, Beckta JM, Bindra RS
    Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol. In press. h
    Eur Urol. 2019 May 9. pii: S0302-2838(19)30358.
    PubMed     Text format    


  66. SIERRA PS
    Re: Felix Preisser, Felix K.H. Chun, Raisa S. Pompe, et al. Persistent Prostate-specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.01.048: Useful Prognostic Info
    Eur Urol. 2019 May 4. pii: S0302-2838(19)30355.
    PubMed     Text format    


  67. LOEB S
    Overactive Surveillance: Is "Conservative" Management for Low-risk Prostate Cancer Too Aggressive?
    Eur Urol. 2019 May 3. pii: S0302-2838(19)30282.
    PubMed     Text format    


  68. DONNELLY DW, Gavin A, Downing A, Hounsome L, et al
    Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom.
    Eur Urol. 2019 May 3. pii: S0302-2838(19)30329.
    PubMed     Text format     Abstract available


  69. MARGEL D, Ber Y, Baniel J
    Re: Optimizing Patient's Selection for Prostate Biopsy: A Single Institution Experience with Multi-parametric MRI and the 4Kscore Test for the Detection of Aggressive Prostate Cancer.
    Eur Urol. 2019 May 2. pii: S0302-2838(19)30338.
    PubMed     Text format    


  70. SUARDI N
    Re: Active Surveillance of Prostate Cancer is a Viable Option in Men Younger than 60 Years.
    Eur Urol. 2019 May 2. pii: S0302-2838(19)30341.
    PubMed     Text format    


  71. GNANAPRAGASAM VJ, Barrett T
    The Quest for the Optimal Prostate Biopsy Regime for the 21st Century.
    Eur Urol. 2019;75:741-742.
    PubMed     Text format    


    April 2019
  72. FLETCHER CE
    The Role of Splicing Regulators in the Emergence of Treatment-induced Neuroendocrine Prostate Cancer: The Next Generation of Drug Targets?
    Eur Urol. 2019 Apr 29. pii: S0302-2838(19)30328.
    PubMed     Text format    


  73. SHARP A, Welti JC, Lambros MBK, Dolling D, et al
    Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Apr 27. pii: S0302-2838(19)30285.
    PubMed     Text format     Abstract available


  74. DEVOS G, De Meerleer G, Joniau S
    Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer?
    Eur Urol. 2019 Apr 25. pii: S0302-2838(19)30327.
    PubMed     Text format     Abstract available


  75. FRASER M
    Separating the Dreadful from the Merely Bad: Towards Prognostic and Predictive Biomarkers in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Apr 19. pii: S0302-2838(19)30284.
    PubMed     Text format    


  76. SANDLER KA, Cook RR, Ciezki JP, Ross AE, et al
    Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.
    Eur Urol. 2019 Apr 13. pii: S0302-2838(19)30208.
    PubMed     Text format     Abstract available


  77. MINERVINI A, Mari A, Campi R, Carini M, et al
    Re: Health Economic Analysis of Open and Robot-assisted Laparoscopic Surgery for Prostate Cancer Within the Prospective Multicentre LAPPRO Trial.
    Eur Urol. 2019 Apr 12. pii: S0302-2838(19)30271.
    PubMed     Text format    


  78. KRETSCHMER A, Tilki D
    Re: Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients with High-risk Prostate Cancer with Rising Prostate-specific Antigen Levels After Primary Local Therapy A Randomized Clinical Trial.
    Eur Urol. 2019 Apr 12. pii: S0302-2838(19)30260.
    PubMed     Text format    


  79. HORN T, Kronke M, Rauscher I, Haller B, et al
    Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in
    Eur Urol. 2019 Apr 12. pii: S0302-2838(19)30278.
    PubMed     Text format     Abstract available


  80. YAXLEY JW
    Will Favourable Functional Results with Salvage Robot-assisted Laparoscopic Radical Prostatectomy Increase the Uptake of Primary Focal Therapy for Localised Prostate Cancer?
    Eur Urol. 2019 Apr 9. pii: S0302-2838(19)30264.
    PubMed     Text format    


  81. STEINECK G, Akre O, Bill-Axelson A
    Solid Science for the Upside but Lack of Solid Science for the Downside-Towards Cutting-edge Prostate-cancer Screening.
    Eur Urol. 2019 Apr 8. pii: S0302-2838(19)30276.
    PubMed     Text format    


  82. VAN DEN BROECK T, Mottet N, Lam T
    Reply to Xueliang Zhou and Xinwei Han's Letter to the Editor re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A System
    Eur Urol. 2019 Apr 6. pii: S0302-2838(19)30255.
    PubMed     Text format    


  83. WERNTZ RP, Eggener SE
    Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015.
    Eur Urol. 2019 Apr 5. pii: S0302-2838(19)30274.
    PubMed     Text format    


  84. CATHELINEAU X, Macek P, Sanchez-Salas R
    Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up.
    Eur Urol. 2019 Apr 4. pii: S0302-2838(19)30262.
    PubMed     Text format    


  85. FRYDENBERG M
    Re: (68)Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2019 Apr 4. pii: S0302-2838(19)30272.
    PubMed     Text format    


  86. MATEO J, Carreira S, de Bono JS
    PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers.
    Eur Urol. 2019 Apr 3. pii: S0302-2838(19)30257.
    PubMed     Text format    


  87. STOCKLE M
    Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up.
    Eur Urol. 2019 Apr 1. pii: S0302-2838(19)30263.
    PubMed     Text format    


  88. ZHOU X, Han X
    Re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. In press. https://doi.org/10.1016/j.eu
    Eur Urol. 2019 Apr 1. pii: S0302-2838(19)30256.
    PubMed     Text format    


  89. SADUN TY, Reiter RE
    Adjusting Our Approach to Multiparametric Magnetic Resonance Imaging-based Targeted Prostate Biopsies: Considerations After the FUTURE Trial.
    Eur Urol. 2019;75:591-592.
    PubMed     Text format    


  90. MARKOWSKI MC, Boorjian SA, Burton JP, Hahn NM, et al
    The Microbiome and Genitourinary Cancer: A Collaborative Review.
    Eur Urol. 2019;75:637-646.
    PubMed     Text format     Abstract available


  91. VAN DER LEEST M, Cornel E, Israel B, Hendriks R, et al
    Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naive Men with Elevated Prostate-specific Antigen: A Large Prospectiv
    Eur Urol. 2019;75:570-578.
    PubMed     Text format     Abstract available


    March 2019
  92. CARLSSON SV, Mansson M, Moss S, Kwiatkowski M, et al
    Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
    Eur Urol. 2019 Mar 27. pii: S0302-2838(19)30196.
    PubMed     Text format     Abstract available


  93. LEIBOWITZ-AMIT R
    Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur
    Eur Urol. 2019 Mar 27. pii: S0302-2838(19)30199.
    PubMed     Text format    


  94. CHEN WS, Aggarwal R, Zhang L, Zhao SG, et al
    Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Mar 27. pii: S0302-2838(19)30206.
    PubMed     Text format     Abstract available


  95. LI Y, Xie N, Chen R, Lee AR, et al
    RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
    Eur Urol. 2019 Mar 22. pii: S0302-2838(19)30197.
    PubMed     Text format     Abstract available


  96. URABE F, Ochiya T, Egawa S
    Re: A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    Eur Urol. 2019 Mar 21. pii: S0302-2838(19)30183.
    PubMed     Text format    


  97. KNUDSEN KE, Feng FY
    Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset.
    Eur Urol. 2019 Mar 15. pii: S0302-2838(19)30191.
    PubMed     Text format    


  98. NAM RK
    Re: Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger than 60 Years.
    Eur Urol. 2019 Mar 14. pii: S0302-2838(19)30189.
    PubMed     Text format    


  99. BRATT O, Holmberg E, Andren O, Carlsson S, et al
    The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS).
    Eur Urol. 2019 Mar 13. pii: S0302-2838(19)30182.
    PubMed     Text format     Abstract available


  100. MOON DH, Basak RS, Usinger DS, Dickerson GA, et al
    Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer.
    Eur Urol. 2019 Mar 8. pii: S0302-2838(19)30169.
    PubMed     Text format     Abstract available


  101. NABID A, Souhami L
    Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Abdenour Nabid, Nathalie Carrier, Andre-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31
    Eur Urol. 2019;75:e63.
    PubMed     Text format    


  102. CONTEDUCA V, Jayaram A, Romero-Laorden N, Wetterskog D, et al
    Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019;75:368-373.
    PubMed     Text format     Abstract available


  103. AHMADZADEHFAR H, Essler M
    Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning.
    Eur Urol. 2019 Mar 1. pii: S0302-2838(19)30175.
    PubMed     Text format    


  104. WALZ J
    What Needs To Be Done Before Prostate Magnetic Resonance Imaging Can Safely Be Applied in the General Population.
    Eur Urol. 2019;75:397-398.
    PubMed     Text format    


  105. VAN HEMELRIJCK M, Ji X, Helleman J, Roobol MJ, et al
    Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.
    Eur Urol. 2019;75:523-531.
    PubMed     Text format     Abstract available


  106. PADHANI AR, Weinreb J, Rosenkrantz AB, Villeirs G, et al
    Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.
    Eur Urol. 2019;75:385-396.
    PubMed     Text format     Abstract available


    February 2019
  107. KARNES RJ, Motterle G
    Re: Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger than 60 Years.
    Eur Urol. 2019 Feb 28. pii: S0302-2838(19)30168.
    PubMed     Text format    


  108. HOFER L, Hohenfellner M
    Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up.
    Eur Urol. 2019 Feb 27. pii: S0302-2838(19)30164.
    PubMed     Text format    


  109. DARCEY E, Pereira G, Salter A, Fritschi L, et al
    The Impact of Lifestyle-related Factors on Survival After a Prostate Cancer Diagnosis.
    Eur Urol. 2019 Feb 27. pii: S0302-2838(19)30151.
    PubMed     Text format    


  110. BURDETT S, Boeve LM, Ingleby FC, Fisher DJ, et al
    Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis.
    Eur Urol. 2019 Feb 27. pii: S0302-2838(19)30111.
    PubMed     Text format     Abstract available


  111. HUGOSSON J, Roobol MJ, Mansson M, Tammela TLJ, et al
    A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
    Eur Urol. 2019 Feb 26. pii: S0302-2838(19)30150.
    PubMed     Text format     Abstract available


  112. WALLIS CJD, Klotz L, Klaassen Z
    Re: Prostate Cancer-specific Mortality Across Gleason Scores in Black vs Nonblack Men.
    Eur Urol. 2019 Feb 25. pii: S0302-2838(19)30162.
    PubMed     Text format    


  113. PRENSNER JR, Feng FY
    "Lincing" the Y Chromosome to Prostate Cancer: TTTY15 Takes Center Stage.
    Eur Urol. 2019 Feb 21. pii: S0302-2838(19)30158.
    PubMed     Text format    


  114. WIRTH M, Fossati N, Albers P, Bangma C, et al
    The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting.
    Eur Urol. 2019 Feb 21. pii: S0302-2838(19)30077.
    PubMed     Text format     Abstract available


  115. MARSHALL CH, Sokolova AO, McNatty AL, Cheng HH, et al
    Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    Eur Urol. 2019 Feb 20. pii: S0302-2838(19)30110.
    PubMed     Text format     Abstract available


  116. LEONGAMORNLERT DA, Saunders EJ, Wakerell S, Whitmore I, et al
    Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel.
    Eur Urol. 2019 Feb 15. pii: S0302-2838(19)30096.
    PubMed     Text format     Abstract available


  117. SHORT CE, Trinh L, James EL
    Effective Technology-based Behaviour Change Interventions in Prostate Cancer Supportive Care: Are We There Yet?
    Eur Urol. 2019 Feb 15. pii: S0302-2838(19)30109.
    PubMed     Text format    


  118. PERERA M, Papa N, Roberts M, Williams M, et al
    Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and M
    Eur Urol. 2019 Feb 14. pii: S0302-2838(19)30095.
    PubMed     Text format     Abstract available


  119. MURTOLA TJ, Syvala H, Riikonen J
    Reply to Jae Heon Kim and Benjamin I. Chung's Letter to the Editor re: Teemu J. Murtola, Heimo Syvala, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Cl
    Eur Urol. 2019 Feb 6. pii: S0302-2838(19)30090.
    PubMed     Text format    


  120. KIM JH, Chung BI
    Re: Timu J. Murtola, Hemo Syvala, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol 2018;74:697-701.
    Eur Urol. 2019 Feb 6. pii: S0302-2838(19)30088.
    PubMed     Text format    


  121. VALE S
    Re: Rano Matta, Christopher J.D. Wallis, Mitchell G. Goldenberg, et al. Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study. Eur Urol 2019;75:3-7: Translati
    Eur Urol. 2019 Feb 4. pii: S0302-2838(19)30089.
    PubMed     Text format    


  122. BENOIST GE, van Oort IM, Burger DM, Koch BCP, et al
    The Combination of Enzalutamide and Opioids: A Painful Pitfall?
    Eur Urol. 2019;75:351-352.
    PubMed     Text format    


  123. CAPOGROSSO P, Vertosick EA, Benfante NE, Eastham JA, et al
    Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last Decade.
    Eur Urol. 2019;75:221-228.
    PubMed     Text format     Abstract available


  124. KLOTZ L, Loblaw A, Sugar L, Moussa M, et al
    Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.
    Eur Urol. 2019;75:300-309.
    PubMed     Text format     Abstract available


    January 2019
  125. SHOAG JE, Tosoian JJ, Salami SS, Barbieri CE, et al
    Unraveling Prostate Cancer Genomics, Pathology, and Magnetic Resonance Imaging Visibility.
    Eur Urol. 2019 Jan 31. pii: S0302-2838(19)30070.
    PubMed     Text format    


  126. VOLTA AD, Formenti A, Berruti A
    Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit.
    Eur Urol. 2019 Jan 30. pii: S0302-2838(19)30069.
    PubMed     Text format     Abstract available


  127. LOEB S, Taylor J, Butaney M, Byrne NK, et al
    Twitter-based Prostate Cancer Journal Club (#ProstateJC) Promotes Multidisciplinary Global Scientific Discussion and Research Dissemination.
    Eur Urol. 2019 Jan 30. pii: S0302-2838(19)30068.
    PubMed     Text format    


  128. HOULAHAN KE, Salmasi A, Sadun TY, Pooli A, et al
    Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer.
    Eur Urol. 2019 Jan 24. pii: S0302-2838(18)31044.
    PubMed     Text format     Abstract available


  129. MAHAL BA, Alshalalfa M, Spratt DE, Davicioni E, et al
    Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores.
    Eur Urol. 2019 Jan 22. pii: S0302-2838(19)30011.
    PubMed     Text format    


  130. KISHAN AU, Hall WA, Spratt DE
    Re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol. In press.
    Eur Urol. 2019 Jan 19. pii: S0302-2838(19)30017.
    PubMed     Text format    


  131. COLE AP, Trinh QD
    Reply to Amar U. Kishan, William Hall, and Daniel Spratt's Letter to the Editor re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachyth
    Eur Urol. 2019 Jan 19. pii: S0302-2838(19)30018.
    PubMed     Text format    


  132. SEMJONOW A, Hense HW, Schlossler K, Simbrich A, et al
    Development and Prospective Randomized Evaluation of a Decision Aid for Prostate-specific Antigen-based Early Detection of Prostate Cancer in Men Aged Between 55 and 69Yr: The PSAInForm Trial.
    Eur Urol. 2019 Jan 18. pii: S0302-2838(19)30009.
    PubMed     Text format     Abstract available


  133. CASTILLO-JIMENEZ DA, Garcia-Perdomo HA
    Re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. Eur Urol. In press
    Eur Urol. 2019 Jan 18. pii: S0302-2838(19)30013.
    PubMed     Text format    


  134. SATHIANATHEN NJ, Konety BR
    Reply to Diana A. Castillo-Jimenez and Herney A. Garcia-Perdomo's Letter to the Editor re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of A
    Eur Urol. 2019 Jan 18. pii: S0302-2838(19)30020.
    PubMed     Text format    


  135. ON BEHALF OF EMA
    Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al.'s Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eu
    Eur Urol. 2019 Jan 15. pii: S0302-2838(18)30957.
    PubMed     Text format    


  136. ZLOTTA AR, Kuk C
    Further Evidence of Differences in Prostate Cancer Biomarkers Between Caucasian and Asian Men.
    Eur Urol. 2019 Jan 11. pii: S0302-2838(18)31046.
    PubMed     Text format    


  137. CARNEIRO B, Dizon DS
    Prostate Cancer Social Media: In YouTube We Trust?
    Eur Urol. 2019 Jan 10. pii: S0302-2838(19)30005.
    PubMed     Text format    


  138. SOORIAKUMARAN P, Pavan N, Wiklund PN, Roach M 3rd, et al
    Surgery Versus Radiation for High-risk Prostate Cancer: The Fight Continues. But Is It Time To Call a Draw and Reach Consensus?
    Eur Urol. 2019 Jan 10. pii: S0302-2838(18)31040.
    PubMed     Text format    


  139. KENFIELD SA, Van Blarigan EL, Ameli N, Lavaki E, et al
    Feasibility, Acceptability, and Behavioral Outcomes from a Technology-enhanced Behavioral Change Intervention (Prostate 8): A Pilot Randomized Controlled Trial in Men with Prostate Cancer.
    Eur Urol. 2019 Jan 9. pii: S0302-2838(18)31048.
    PubMed     Text format     Abstract available


  140. VANDEKERKHOVE G, Struss WJ, Annala M, Kallio HML, et al
    Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Eur Urol. 2019 Jan 9. pii: S0302-2838(18)31050.
    PubMed     Text format     Abstract available


  141. SHAH TT, Peters M, Eldred-Evans D, Miah S, et al
    Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry.
    Eur Urol. 2019 Jan 8. pii: S0302-2838(18)31036.
    PubMed     Text format     Abstract available


  142. MURPHY DG, Azad AA, Sandhu S, Violet J, et al
    Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics.
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31047.
    PubMed     Text format    


  143. CIRIACO P, Briganti A, Bernabei A, Gandaglia G, et al
    Safety and Early Oncologic Outcomes of Lung Resection in Patients with Isolated Pulmonary Recurrent Prostate Cancer: A Single-center Experience.
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31035.
    PubMed     Text format     Abstract available


  144. VIS AN, Boeve LMS
    Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31029.
    PubMed     Text format    


  145. KRETSCHMER A, Gleave ME
    Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE).
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31043.
    PubMed     Text format    


  146. HEIDEGGER I, Pichler R
    Re: Peter K.-F. Chiu, Chi-Fai Ng, Axel Semjonow, et al. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asia
    Eur Urol. 2019 Jan 4. pii: S0302-2838(18)31049.
    PubMed     Text format    


  147. YANG DD, Mahal BA, Muralidhar V, Martin NE, et al
    Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
    Eur Urol. 2019;75:35-41.
    PubMed     Text format     Abstract available


  148. MORGANS AK
    An Imprecise Path to Precision Medicine.
    Eur Urol. 2019;75:193-194.
    PubMed     Text format    


  149. ZHOU AG, Salles DC, Samarska IV, Epstein JI, et al
    How Are Gleason Scores Categorized in the Current Literature: An Analysis and Comparison of Articles Published in 2016-2017.
    Eur Urol. 2019;75:25-31.
    PubMed     Text format     Abstract available


    December 2018
  150. KHALAF DJ, Sunderland K, Eigl BJ, Kollmannsberger CK, et al
    Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
    Eur Urol. 2018 Dec 24. pii: S0302-2838(18)31020.
    PubMed     Text format     Abstract available


  151. DI LORENZO G, Buonerba C
    Oligometastatic Prostate Cancer: Is it Only a Matter of Perspective?
    Eur Urol. 2018 Dec 24. pii: S0302-2838(18)30998.
    PubMed     Text format     Abstract available


  152. GREGUCCI F, Fiorentino A
    Re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primar
    Eur Urol. 2018 Dec 24. pii: S0302-2838(18)31030.
    PubMed     Text format    


  153. DENTON BT, Hawley ST, Morgan TM
    Optimizing Prostate Cancer Surveillance: Using Data-driven Models for Informed Decision-making.
    Eur Urol. 2018 Dec 18. pii: S0302-2838(18)30965.
    PubMed     Text format    


  154. LOHAUS F, Zophel K, Lock S, Wirth M, et al
    Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
    Eur Urol. 2018 Dec 18. pii: S0302-2838(18)30954.
    PubMed     Text format     Abstract available


  155. MATTA R, Chapple CR, Fisch M, Heidenreich A, et al
    Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.
    Eur Urol. 2018 Dec 17. pii: S0302-2838(18)30962.
    PubMed     Text format     Abstract available


  156. OSTERGREN PB, Murtola TJ, Fode M
    Are Biomarker-driven Inclusion and Symptom Control Endpoints the Future of Phase 3 Trials in Metastatic Castration-resistant Prostate Cancer? Lessons from COMET-2.
    Eur Urol. 2018 Dec 17. pii: S0302-2838(18)31021.
    PubMed     Text format    


  157. PADHANI AR, Haider MA, Villers A, Barentsz JO, et al
    Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: What We See and What We Miss.
    Eur Urol. 2018 Dec 15. pii: S0302-2838(18)30963.
    PubMed     Text format    


  158. WEI Y, Li T, Liu L
    Re: Alberto Briganti, Nicola Fossati, James W.F. Catto, et al. Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:357-68.
    Eur Urol. 2018 Dec 15. pii: S0302-2838(18)31001.
    PubMed     Text format    


  159. GOKCE A, Gul D
    Re: Mark Douglas Tyson II, Tatsuki Koyama, Dan Lee, et al. Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results. Eur Urol 2018;74:26-33.
    Eur Urol. 2018 Dec 14. pii: S0302-2838(18)31000.
    PubMed     Text format    


  160. DAL PRA A, Abramowitz M, Pollack A
    Local Treatment in Metastatic Prostate Cancer: A Cultural Shift Confronts Power and Selection.
    Eur Urol. 2018 Dec 12. pii: S0302-2838(18)30958.
    PubMed     Text format    


  161. HAMID AA, Gray KP, Shaw G, MacConaill LE, et al
    Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Eur Urol. 2018 Dec 12. pii: S0302-2838(18)30949.
    PubMed     Text format     Abstract available


  162. NYBERG T, Govindasami K, Leslie G, Dadaev T, et al
    Homeobox B13 G84E Mutation and Prostate Cancer Risk.
    Eur Urol. 2018 Dec 7. pii: S0302-2838(18)30872.
    PubMed     Text format     Abstract available


  163. XIAO G, Yao J, Kong D, Ye C, et al
    The Long Noncoding RNA TTTY15, Which Is Located on the Y Chromosome, Promotes Prostate Cancer Progression by Sponging let-7.
    Eur Urol. 2018 Dec 7. pii: S0302-2838(18)30869.
    PubMed     Text format     Abstract available


  164. RUD E, Lauritzen P, Baco E
    Re: Henrik Gronberg, Martin Eklund, Wolfgang Picker, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.06.022.
    Eur Urol. 2018 Dec 4. pii: S0302-2838(18)30951.
    PubMed     Text format    


  165. BASCH EM, Scholz M, de Bono JS, Vogelzang N, et al
    Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.
    Eur Urol. 2018 Dec 4. pii: S0302-2838(18)30932.
    PubMed     Text format     Abstract available


  166. BURNS JA, Weiner AB, Catalona WJ, Li EV, et al
    Inflammatory Bowel Disease and the Risk of Prostate Cancer.
    Eur Urol. 2018 Dec 4. pii: S0302-2838(18)30938.
    PubMed     Text format     Abstract available


  167. WEGELIN O, Exterkate L, van der Leest M, Kummer JA, et al
    The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies.
    Eur Urol. 2018 Dec 3. pii: S0302-2838(18)30939.
    PubMed     Text format     Abstract available


  168. EKLUND M, Strom P, Gronberg H, Nordstrom T, et al
    Reply to Erik Rud, Peter Lauritzen, and Eduard Baco's Letter to the Editor re: Henrik Gronberg, Martin Eklund, Wolfgang Picker, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance
    Eur Urol. 2018 Dec 1. pii: S0302-2838(18)30950.
    PubMed     Text format    


  169. SARTOR O
    Synergistic Interactions: Targeted Radiopharmaceuticals and Homologous Recombination Repair Alterations in Prostate Cancer.
    Eur Urol. 2018 Dec 1. pii: S0302-2838(18)30940.
    PubMed     Text format    


  170. KEARNS JT, Newcomb LF, Lin DW
    Reply to Runqiang Yuan's Letter to the Editor re: James T. Kearns, Anna V. Faino, Lisa F. Newcomb, et al. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Stud
    Eur Urol. 2018;74:e151.
    PubMed     Text format    


  171. YUAN R
    Re: James T. Kearns, Anna V. Faino, Lisa F. Newcomb, et al. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. Eur Urol 2018;73:706-12.
    Eur Urol. 2018;74:e149-e150.
    PubMed     Text format    


    November 2018
  172. JOHNSON DC, Raman SS, Mirak SA, Kwan L, et al
    Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.
    Eur Urol. 2018 Nov 30. pii: S0302-2838(18)30930.
    PubMed     Text format     Abstract available


  173. MOSCHINI M, Zaffuto E, Mattei A, Karakiewicz PI, et al
    Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostat
    Eur Urol. 2018 Nov 30. pii: S0302-2838(18)30942.
    PubMed     Text format    


  174. BOEVE LMS, Vis AN
    Reply to Herney Andres Garcia-Perdomo's Letter to the Editor re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurr
    Eur Urol. 2018 Nov 29. pii: S0302-2838(18)30933.
    PubMed     Text format    


  175. MOSCHINI M, Zaffuto E, Mattei A, Karakiewicz PI, et al
    Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical
    Eur Urol. 2018 Nov 29. pii: S0302-2838(18)30941.
    PubMed     Text format    


  176. HAMID S, Donaldson IA, Hu Y, Rodell R, et al
    The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification.
    Eur Urol. 2018 Nov 29. pii: S0302-2838(18)30592.
    PubMed     Text format     Abstract available


  177. DE BRUYCKER A, De Bleser E, Decaestecker K, Fonteyne V, et al
    Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates.
    Eur Urol. 2018 Nov 28. pii: S0302-2838(18)30839.
    PubMed     Text format     Abstract available


  178. FIORENTINO A, Errico A, Scarcia M
    Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol
    Eur Urol. 2018 Nov 27. pii: S0302-2838(18)30881.
    PubMed     Text format    


  179. LOEB S, Sengupta S, Butaney M, Macaluso JN Jr, et al
    Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube.
    Eur Urol. 2018 Nov 27. pii: S0302-2838(18)30854.
    PubMed     Text format     Abstract available


  180. ZHOU Z, Zhou Y, Yan W
    Re: Stephanie Guillaumier, Max Peters, Manit Arya, et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur Urol 2018;74:422-9.
    Eur Urol. 2018 Nov 27. pii: S0302-2838(18)30935.
    PubMed     Text format    


  181. BECKMANN K, Garmo H, Adolfsson J, Bosco C, et al
    Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Eur Urol. 2018 Nov 26. pii: S0302-2838(18)30879.
    PubMed     Text format     Abstract available


  182. GARCIA-PERDOMO HA
    Re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primar
    Eur Urol. 2018 Nov 23. pii: S0302-2838(18)30929.
    PubMed     Text format    


  183. ZAORSKY NG, Spratt DE, Blanchard P
    Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol
    Eur Urol. 2018 Nov 22. pii: S0302-2838(18)30882.
    PubMed     Text format    


  184. LAM TBL, MacLennan S, Plass K, Willemse PM, et al
    Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer.
    Eur Urol. 2018 Nov 22. pii: S0302-2838(18)30866.
    PubMed     Text format    


  185. HECK MM, Tauber R, Schwaiger S, Retz M, et al
    Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with (177)Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Nov 22. pii: S0302-2838(18)30873.
    PubMed     Text format     Abstract available


  186. CIMADAMORE A, Scarpelli M, Santoni M, Cheng L, et al
    Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. J Vas
    Eur Urol. 2018 Nov 21. pii: S0302-2838(18)30895.
    PubMed     Text format    


  187. BOEVE LMS, Verhagen PCMS, Vis AN
    Reply to Ashwin Shinde, Richard Li, Arya Amini, and Scott Glaser's Letter to the Editor re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Th
    Eur Urol. 2018 Nov 21. pii: S0302-2838(18)30864.
    PubMed     Text format    


  188. TILKI D, Evans CP
    Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial.
    Eur Urol. 2018 Nov 19. pii: S0302-2838(18)30868.
    PubMed     Text format    


  189. MAHON KL, Qu W, Lin HM, Spielman C, et al
    Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
    Eur Urol. 2018 Nov 19. pii: S0302-2838(18)30855.
    PubMed     Text format     Abstract available


  190. MATEO J, Carles J
    Towards a New Classification for Metastatic Prostate Cancer.
    Eur Urol. 2018 Nov 19. pii: S0302-2838(18)30862.
    PubMed     Text format    


  191. SHINDE A, Li R, Amini A, Glaser S, et al
    Re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primar
    Eur Urol. 2018 Nov 18. pii: S0302-2838(18)30865.
    PubMed     Text format    


  192. O'SULLIVAN JM, Heinrich D, James ND, Nilsson S, et al
    The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Nov 16. pii: S0302-2838(18)30857.
    PubMed     Text format    


  193. DE MAN K, Ost P
    Re: [(177)Lu]-PSMA-617 Radionuclide Treatment in Patients with Metastatic Castration-resistant Prostate Cancer (LuPSMA Trial): A Single-centre, Single-arm, Phase 2 Study.
    Eur Urol. 2018 Nov 14. pii: S0302-2838(18)30859.
    PubMed     Text format    


  194. SATHIANATHEN NJ, Konety BR, Alarid-Escudero F, Lawrentschuk N, et al
    Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
    Eur Urol. 2018 Nov 10. pii: S0302-2838(18)30853.
    PubMed     Text format     Abstract available


  195. BERG S, Cole AP, Krimphove MJ, Nabi J, et al
    Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer.
    Eur Urol. 2018 Nov 9. pii: S0302-2838(18)30820.
    PubMed     Text format     Abstract available


  196. OSSES DF, Remmers S, Schroder FH, van der Kwast T, et al
    Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up.
    Eur Urol. 2018 Nov 9. pii: S0302-2838(18)30851.
    PubMed     Text format     Abstract available


  197. GANDAGLIA G, Soligo M, Battaglia A, Muilwijk T, et al
    Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes.
    Eur Urol. 2018 Nov 5. pii: S0302-2838(18)30837.
    PubMed     Text format     Abstract available


  198. CHIU PK, Ng CF, Semjonow A, Zhu Y, et al
    A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings.
    Eur Urol. 2018 Nov 2. pii: S0302-2838(18)30842.
    PubMed     Text format     Abstract available


    October 2018
  199. CANTER DJ, Reid J, Latsis M, Variano M, et al
    Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.
    Eur Urol. 2018 Oct 31. pii: S0302-2838(18)30816.
    PubMed     Text format     Abstract available


  200. PLOUSSARD G, Gandaglia G, Borgmann H, de Visschere P, et al
    Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review.
    Eur Urol. 2018 Oct 31. pii: S0302-2838(18)30836.
    PubMed     Text format     Abstract available


  201. BRATT O, Lamb AD
    Genetic Reasons to Walk the Extra Mile to Prevent Prostate Cancer.
    Eur Urol. 2018 Oct 29. pii: S0302-2838(18)30807.
    PubMed     Text format    


  202. GHADJAR P, Wiegel T
    Re: Abdenour Nabid, Nathalie Carrier, Andre-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31.
    Eur Urol. 2018 Oct 26. pii: S0302-2838(18)30818.
    PubMed     Text format    


  203. ROOBOL MJ
    Active Surveillance for Low-risk Prostate Cancer: Will it Become Obsolete?
    Eur Urol. 2018 Oct 25. pii: S0302-2838(18)30809.
    PubMed     Text format    


  204. GANDAGLIA G, Ploussard G, Valerio M, Mattei A, et al
    A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies.
    Eur Urol. 2018 Oct 17. pii: S0302-2838(18)30753.
    PubMed     Text format     Abstract available


  205. VAN DEN BROECK T, van den Bergh RCN, Arfi N, Gross T, et al
    Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.
    Eur Urol. 2018 Oct 17. pii: S0302-2838(18)30752.
    PubMed     Text format     Abstract available


  206. ZAFEIRIOU Z, Bianchini D, Chandler R, Rescigno P, et al
    Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.
    Eur Urol. 2018 Oct 16. pii: S0302-2838(18)30738.
    PubMed     Text format     Abstract available


  207. ANTONARAKIS ES, Shaukat F, Isaacsson Velho P, Kaur H, et al
    Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.
    Eur Urol. 2018 Oct 15. pii: S0302-2838(18)30750.
    PubMed     Text format     Abstract available


  208. KASIVISVANATHAN V, Ambrosi A, Giganti F, Chau E, et al
    A Dedicated Prostate MRI Teaching Course Improves the Ability of the Urologist to Interpret Clinically Significant Prostate Cancer on Multiparametric MRI.
    Eur Urol. 2018 Oct 13. pii: S0302-2838(18)30721.
    PubMed     Text format    


  209. VICKERS AJ, Lilja H, Assel M
    Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-u
    Eur Urol. 2018 Oct 13. pii: S0302-2838(18)30743.
    PubMed     Text format    


  210. PENNEY KL, Loda M, Stampfer MJ
    Re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening
    Eur Urol. 2018 Oct 12. pii: S0302-2838(18)30744.
    PubMed     Text format    


  211. AUFFENBERG GB, Ghani KR, Ramani S, Usoro E, et al
    askMUSIC: Leveraging a Clinical Registry to Develop a New Machine Learning Model to Inform Patients of Prostate Cancer Treatments Chosen by Similar Men.
    Eur Urol. 2018 Oct 11. pii: S0302-2838(18)30740.
    PubMed     Text format     Abstract available


  212. CARTER HB, Helfand B, Mamawala M, Wu Y, et al
    Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
    Eur Urol. 2018 Oct 8. pii: S0302-2838(18)30684.
    PubMed     Text format     Abstract available


  213. PERNAR CH, Ebot EM, Pettersson A, Graff RE, et al
    A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
    Eur Urol. 2018 Oct 6. pii: S0302-2838(18)30730.
    PubMed     Text format     Abstract available


  214. FOSSATI N, Suardi N, Gandaglia G, Bravi CA, et al
    Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.
    Eur Urol. 2018 Oct 6. pii: S0302-2838(18)30659.
    PubMed     Text format     Abstract available


  215. MOSCHINI M, Zaffuto E, Karakiewicz PI, Andrea DD, et al
    External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
    Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30722.
    PubMed     Text format     Abstract available


  216. ISAACSSON VELHO P, Qazi F, Hassan S, Carducci MA, et al
    Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
    Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30729.
    PubMed     Text format     Abstract available


  217. CULIG Z
    Identification of Potential Novel Candidates for Understanding Racial Differences in Prostate Cancer.
    Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30726.
    PubMed     Text format    


  218. SIVA S, Bressel M, Murphy DG, Shaw M, et al
    Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
    Eur Urol. 2018;74:455-462.
    PubMed     Text format     Abstract available


  219. TOSCO L, Briganti A, D'amico AV, Eastham J, et al
    Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer.
    Eur Urol. 2018 Oct 1. pii: S0302-2838(18)30549.
    PubMed     Text format     Abstract available


  220. OST P
    It Ain't Over Till the Fat Lady Sings: The POPSTAR Trial.
    Eur Urol. 2018;74:463-464.
    PubMed     Text format    


  221. GORIN MA, Walsh PC
    Magnetic Resonance Imaging Prior to First Prostate Biopsy-Are we there yet?
    Eur Urol. 2018;74:409-410.
    PubMed     Text format    


    September 2018
  222. NORDSTROM T, Lindberg J, Eklund M
    Towards Next-generation Urine-based Prostate Cancer Risk Stratification.
    Eur Urol. 2018 Sep 28. pii: S0302-2838(18)30709.
    PubMed     Text format    


  223. OISHI M, Gill IS, Ashrafi AN, Lin-Brande M, et al
    Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up.
    Eur Urol. 2018 Sep 28. pii: S0302-2838(18)30654.
    PubMed     Text format     Abstract available


  224. GRAFF RE, Kachuri L, Witte JS
    Personalized Prostate Cancer Screening Based on a Single Midlife Prostate-specific Antigen Measurement.
    Eur Urol. 2018 Sep 26. pii: S0302-2838(18)30681.
    PubMed     Text format    


  225. DEEK MP, Phillips RM, Haffner M, Tran PT, et al
    Is Androgen Deprivation Therapy "Another Deficient Therapy" for Gleason Score 9-10 Prostate Cancer?
    Eur Urol. 2018 Sep 26. pii: S0302-2838(18)30715.
    PubMed     Text format    


  226. BOEVE LMS, Hulshof MCCM, Vis AN, Zwinderman AH, et al
    Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical
    Eur Urol. 2018 Sep 25. pii: S0302-2838(18)30658.
    PubMed     Text format     Abstract available


  227. SHINDE A, Li R, Glaser S, Amini A, et al
    Node-positive Nonmetastatic Prostate Cancer: Time to Reconsider Prognostic Staging?
    Eur Urol. 2018 Sep 24. pii: S0302-2838(18)30667.
    PubMed     Text format     Abstract available


  228. TONON L, Fromont G, Boyault S, Thomas E, et al
    Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men.
    Eur Urol. 2018 Sep 20. pii: S0302-2838(18)30618.
    PubMed     Text format     Abstract available


  229. MATTA R, Wallis CJD, Goldenberg MG, Hird AE, et al
    Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study.
    Eur Urol. 2018 Sep 18. pii: S0302-2838(18)30630.
    PubMed     Text format     Abstract available


  230. PRESTON MA, Gerke T, Carlsson SV, Signorello L, et al
    Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30627.
    PubMed     Text format     Abstract available


  231. VAN DER POEL HG, van den Bergh RCN, Briers E, Cornford P, et al
    Reply to Massimo Valerio, Mark Emberton, and Hashim U. Ahmed's Letter to the Editor re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Posi
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30645.
    PubMed     Text format    


  232. MCKIERNAN J, Donovan MJ, Margolis E, Partin A, et al
    A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30604.
    PubMed     Text format     Abstract available


  233. WEINER AB, Schaeffer EM, Eggener SE
    "Real-world" Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer.
    Eur Urol. 2018 Sep 14. pii: S0302-2838(18)30643.
    PubMed     Text format    


  234. VALERIO M, Emberton M, Ahmed HU
    Re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91.
    Eur Urol. 2018 Sep 14. pii: S0302-2838(18)30646.
    PubMed     Text format    


  235. WALLIS CJD, Krakowsky Y, Finelli A
    Low Testosterone and Prostate Cancer: Is the Protection Real?
    Eur Urol. 2018 Sep 5. pii: S0302-2838(18)30616.
    PubMed     Text format    


  236. LOVF M, Zhao S, Axcrona U, Johannessen B, et al
    Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.
    Eur Urol. 2018 Sep 1. pii: S0302-2838(18)30594.
    PubMed     Text format     Abstract available


  237. KENDALL MC
    Re: Karl H. Pang, Ruth Groves, Suresh Venugopal, Aidan P. Noon, James W.F. Catto. Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. Eur Urol 2018;73:363-71.
    Eur Urol. 2018;74:e65.
    PubMed     Text format    


  238. PANG KH, Groves R, Catto JWF
    Reply to Mark C. Kendall's Letter to the Editor re: Karl H. Pang, Ruth Groves, Suresh Venugopal, Aidan P. Noon, James W.F. Catto. Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. Eur Urol 2018;73:363-71.
    Eur Urol. 2018;74:e66.
    PubMed     Text format    


    August 2018
  239. ALLOTT EH, Freeman MR, Freedland SJ
    Statin Therapy to Improve Prostate Cancer Outcomes: Who, When, and for How Long?
    Eur Urol. 2018 Aug 31. pii: S0302-2838(18)30597.
    PubMed     Text format    


  240. DALL'ERA MA, De Vere White RW
    New Insights into Ejaculatory Frequency and Prostate Cancer Risk: Association, Causation, or What Do We Have to Lose?
    Eur Urol. 2018 Aug 31. pii: S0302-2838(18)30599.
    PubMed     Text format    


  241. GINSBURG KB, Auffenberg GB, Qi J, Powell IJ, et al
    Risk of Becoming Lost to Follow-up During Active Surveillance for Prostate Cancer.
    Eur Urol. 2018 Aug 31. pii: S0302-2838(18)30595.
    PubMed     Text format     Abstract available


  242. MASON M
    Re: Enzalutamide in Men with Nonmetastatic, Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Aug 31. pii: S0302-2838(18)30563.
    PubMed     Text format    


  243. FONTEYNE V, Ost P
    Current Insights in the Management of High-risk Prostate Cancer: Still More Questions than Answers.
    Eur Urol. 2018 Aug 30. pii: S0302-2838(18)30598.
    PubMed     Text format    


  244. REIS LO
    Metastasis-free Survival-Progress or Lowering the Bar on Nonmetastatic Prostate Cancer?
    Eur Urol. 2018 Aug 28. pii: S0302-2838(18)30603.
    PubMed     Text format    


  245. FORSMARK A, Gehrman J, Angenete E, Bjartell A, et al
    Health Economic Analysis of Open and Robot-assisted Laparoscopic Surgery for Prostate Cancer Within the Prospective Multicentre LAPPRO Trial.
    Eur Urol. 2018 Aug 21. pii: S0302-2838(18)30560.
    PubMed     Text format     Abstract available


  246. MATEO J, Fizazi K, Gillessen S, Heidenreich A, et al
    Managing Nonmetastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Aug 14. pii: S0302-2838(18)30557.
    PubMed     Text format     Abstract available


  247. CIMADAMORE A, Scarpelli M, Cheng L, Lopez-Beltran A, et al
    Re: Isabel Rauscher, Charlotte Duwel, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for (68)Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Rec
    Eur Urol. 2018 Aug 6. pii: S0302-2838(18)30556.
    PubMed     Text format    


  248. MONTIRONI R, Cheng L, Cimadamore A, Lopez-Beltran A, et al
    Prostate Cancer Grading: Are We Heading Towards Grade Grouping Version 2?
    Eur Urol. 2018 Aug 6. pii: S0302-2838(18)30555.
    PubMed     Text format    


  249. ALBERTS AR, Roobol MJ, Verbeek JFM, Schoots IG, et al
    Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Eur Urol. 2018 Aug 3. pii: S0302-2838(18)30553.
    PubMed     Text format     Abstract available


  250. WATTS EL, Appleby PN, Perez-Cornago A, Bueno-de-Mesquita HB, et al
    Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies.
    Eur Urol. 2018 Aug 1. pii: S0302-2838(18)30546.
    PubMed     Text format     Abstract available


    July 2018
  251. BOUTROS PC
    The Promise and Perils of Sequencing Individual Prostate Cancer Nuclei.
    Eur Urol. 2018 Jul 31. pii: S0302-2838(18)30550.
    PubMed     Text format    


  252. D'ANDREA D, Shariat SF, Soria F
    Re: Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
    Eur Urol. 2018 Jul 30. pii: S0302-2838(18)30544.
    PubMed     Text format    


  253. PREISSER F, Mazzone E, Nazzani S, Bandini M, et al
    Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer.
    Eur Urol. 2018 Jul 20. pii: S0302-2838(18)30484.
    PubMed     Text format     Abstract available


  254. CAVARRETTA I, Mancini N, Salonia A
    Analysis of the Enteric Microbiome: First Tentative Steps Towards a Comprehensive Work-up of Prostate Cancer?
    Eur Urol. 2018 Jul 20. pii: S0302-2838(18)30509.
    PubMed     Text format    


  255. MURTOLA TJ, Syvala H, Tolonen T, Helminen M, et al
    Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial.
    Eur Urol. 2018 Jul 18. pii: S0302-2838(18)30465.
    PubMed     Text format     Abstract available


  256. MODI PK, Morgan TM
    Tradeoffs in Refining the Diagnosis of Prostate Cancer.
    Eur Urol. 2018 Jul 18. pii: S0302-2838(18)30486.
    PubMed     Text format    


  257. COONEY KA, Beebe-Dimmer JL
    Finding a Needle in the Haystack: The Search for Germline Variants Associated with Prostate Cancer Clinical Outcomes.
    Eur Urol. 2018 Jul 17. pii: S0302-2838(18)30479.
    PubMed     Text format    


  258. MAHAL BA, Yang DD, Nguyen PL
    Reply to John T. Leppert and James D. Brooks' Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. In press. htt
    Eur Urol. 2018 Jul 17. pii: S0302-2838(18)30471.
    PubMed     Text format    


  259. LAWRENCE MG, Obinata D, Sandhu S, Selth LA, et al
    Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.
    Eur Urol. 2018 Jul 13. pii: S0302-2838(18)30445.
    PubMed     Text format     Abstract available


  260. CRABB SJ
    Therapeutic Discovery for Castration Resistant Prostate Cancer: Patient-derived Xenograft Modelling Brings New Options to the Table.
    Eur Urol. 2018 Jul 12. pii: S0302-2838(18)30477.
    PubMed     Text format    


  261. LEPPERT JT, Brooks JD
    Re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.01.043.
    Eur Urol. 2018 Jul 12. pii: S0302-2838(18)30472.
    PubMed     Text format    


  262. LISS MA, White JR, Goros M, Gelfond J, et al
    Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer.
    Eur Urol. 2018 Jul 11. pii: S0302-2838(18)30461.
    PubMed     Text format     Abstract available


  263. MURPHY DG, Tilki D
    Getting the Balance Right-The Benefits and Uncertainties of Focal Therapy for Significant Prostate Cancer.
    Eur Urol. 2018 Jul 11. pii: S0302-2838(18)30463.
    PubMed     Text format    


  264. SWEENEY CJ
    Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next?
    Eur Urol. 2018 Jul 11. pii: S0302-2838(18)30464.
    PubMed     Text format    


  265. GRONBERG H, Eklund M, Picker W, Aly M, et al
    Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.
    Eur Urol. 2018 Jul 9. pii: S0302-2838(18)30447.
    PubMed     Text format     Abstract available


  266. LI W, Middha M, Bicak M, Sjoberg DD, et al
    Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.
    Eur Urol. 2018 Jul 7. pii: S0302-2838(18)30446.
    PubMed     Text format     Abstract available


  267. NABID A, Carrier N, Martin AG, Bahary JP, et al
    Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.
    Eur Urol. 2018 Jul 3. pii: S0302-2838(18)30443.
    PubMed     Text format     Abstract available


  268. XIE W, D'Amico AV
    Eighteen Months of Androgen Deprivation Therapy in Men with High-risk Prostate Cancer and the Risk of Death.
    Eur Urol. 2018 Jul 2. pii: S0302-2838(18)30451.
    PubMed     Text format    


  269. MOORE C
    Can Negative Prostate Magnetic Resonance Imaging Give Us the Reassurance We Need To Avoid Standard Biopsy? An Evidence-based Practical Approach.
    Eur Urol. 2018;74:55-56.
    PubMed     Text format    


  270. GANDAGLIA G, Bravi CA, Dell'Oglio P, Mazzone E, et al
    The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy.
    Eur Urol. 2018;74:4-7.
    PubMed     Text format     Abstract available


  271. OGAYA-PINIES G, Kadakia Y, Palayapalayam-Ganapathi H, Woodlief T, et al
    Use of Scaffolding Tissue Biografts To Bolster Vesicourethral Anastomosis During Salvage Robot-assisted Prostatectomy Reduces Leak Rates and Catheter Times.
    Eur Urol. 2018;74:92-98.
    PubMed     Text format     Abstract available


    June 2018
  272. GUILLAUMIER S, Peters M, Arya M, Afzal N, et al
    A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.
    Eur Urol. 2018 Jun 27. pii: S0302-2838(18)30431.
    PubMed     Text format     Abstract available


  273. SU F, Zhang W, Zhang D, Zhang Y, et al
    Spatial Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-nucleus Sequencing.
    Eur Urol. 2018 Jun 22. pii: S0302-2838(18)30430.
    PubMed     Text format     Abstract available


  274. BRIGANTI A, Fossati N, Catto JWF, Cornford P, et al
    Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018.
    Eur Urol. 2018 Jun 21. pii: S0302-2838(18)30433.
    PubMed     Text format     Abstract available


  275. HAIDL F, Pfister D, Heidenreich A
    Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients.
    Eur Urol. 2018 Jun 15. pii: S0302-2838(18)30419.
    PubMed     Text format    


  276. WILCZAK W, Wittmer C, Clauditz T, Minner S, et al
    Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.
    Eur Urol. 2018 Jun 13. pii: S0302-2838(18)30423.
    PubMed     Text format     Abstract available


  277. SPRATT DE, Schaeffer EM
    Transcriptomic Heterogeneity of Favorable-risk Prostate Cancer: Time To Move Past Cancer of the Prostate Risk Assessment (CAPRA) to Clinical-genomic Risk.
    Eur Urol. 2018 Jun 12. pii: S0302-2838(18)30426.
    PubMed     Text format    


  278. AMINSHARIFI A, Polascik TJ
    Re: Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy with Brachytherapy Boost and Disease Progression and Mortality in Patients with Gleason Score 9-10 Prostate Cancer.
    Eur Urol. 2018 Jun 8. pii: S0302-2838(18)30420.
    PubMed     Text format    


  279. NAIR R, Porpiglia F, Zargar H
    Re: MRI-targeted or Standard Biopsy for Prostate-cancer Diagnosis.
    Eur Urol. 2018 Jun 6. pii: S0302-2838(18)30418.
    PubMed     Text format    


  280. MEHRA N, Dolling D, de Bono J
    Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant P
    Eur Urol. 2018 Jun 1. pii: S0302-2838(18)30364.
    PubMed     Text format    


  281. BHINDI B, Karnes RJ
    Novel Nonsteroidal Antiandrogens and Overall Survival in Nonmetastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Jun 1. pii: S0302-2838(18)30370.
    PubMed     Text format    


  282. MONTIRONI R, Cheng L, Lopez-Beltran A, Scarpelli M, et al
    Re: A Novel Tool for Predicting Extracapsular Extension During Graded Partial Nerve Sparing in Radical Prostatectomy.
    Eur Urol. 2018;73:978-980.
    PubMed     Text format    


  283. LOMBARDO R, Bosch JLHR, Burkhard FC, Tubaro A, et al
    Re: A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control After Robotic Assisted Radical Prostatectomy.
    Eur Urol. 2018;73:980-981.
    PubMed     Text format    


  284. SPAHN M, Fehr JL
    Multiparametric Magnetic Resonance Imaging for Prostate-specific Antigen Recurrence After Radical Prostatectomy: Are We Leaving the "One Treatment Fits All Approach" and Moving Towards Personalized Imaging-guided Treatment?
    Eur Urol. 2018;73:888-889.
    PubMed     Text format    


  285. EGGENER S
    Nodal Metastases at Radical Prostatectomy: More Aggressive Disease Warrants Consideration of Multimodal Treatment.
    Eur Urol. 2018;73:897-898.
    PubMed     Text format    


  286. KASS-ILIYYA A, Jovic G, Murphy C, Fisher C, et al
    Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial.
    Eur Urol. 2018;73:968-976.
    PubMed     Text format     Abstract available


  287. SHARMA V, Nehra A, Colicchia M, Westerman ME, et al
    Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.
    Eur Urol. 2018;73:879-887.
    PubMed     Text format     Abstract available


    May 2018
  288. COOPERBERG MR, Erho N, Chan JM, Feng FY, et al
    The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer.
    Eur Urol. 2018 May 28. pii: S0302-2838(18)30362.
    PubMed     Text format     Abstract available


  289. CONTEDUCA V, Gurioli G, De Giorgi U
    Re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press.
    Eur Urol. 2018 May 23. pii: S0302-2838(18)30363.
    PubMed     Text format    


  290. LUGHEZZANI G, Buffi NM, Lazzeri M
    Diagnostic Pathway of Patients with a Clinical Suspicion of Prostate Cancer: Does One Size Fit All?
    Eur Urol. 2018 May 23. pii: S0302-2838(18)30361.
    PubMed     Text format    


  291. DONOVAN JL, Hamdy FC
    Time for a "Radical" Change to Active Surveillance for Prostate Cancer?
    Eur Urol. 2018 May 17. pii: S0302-2838(18)30357.
    PubMed     Text format    


  292. VICKERS A, Nordstrom T, Assel M, Lilja H, et al
    Re: Tobias Nordstrom, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Gronberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Eur Urol 2015;68:139-46.
    Eur Urol. 2018 May 3. pii: S0302-2838(18)30333.
    PubMed     Text format    


  293. GONG J, Omlin A, Pal SK, Hsu J, et al
    Influence of an International Consensus Conference on Practice Patterns in Advanced Prostate Cancer.
    Eur Urol. 2018 May 3. pii: S0302-2838(18)30330.
    PubMed     Text format    


  294. KNIPPER S, Graefen M
    Palliative Radical Prostatectomy in Men with Metastatic Castration-resistant Prostate Cancer: Only When Your Back Is Against the Wall!
    Eur Urol. 2018 May 3. pii: S0302-2838(18)30334.
    PubMed     Text format    


  295. CAMPODONICO F, Ennas M, Introini C
    Re: Ettore Di Trapani, Alessandro Nini, Irene Locatelli, et al. Development of the First Model of Radical Prostatectomy in the Mouse: A Feasibility Study. Eur Urol 2018;73:482-4.
    Eur Urol. 2018;73:e133.
    PubMed     Text format    


  296. AVULOVA S, Smith JA Jr
    Is Comparison of Robotic to Open Radical Prostatectomy Still Relevant?
    Eur Urol. 2018;73:672-673.
    PubMed     Text format    


  297. CHIN JL
    Re: Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy.
    Eur Urol. 2018;73:808.
    PubMed     Text format    


  298. MONTIRONI R, Cheng L, Scarpelli M, Lopez-Beltran A, et al
    From Gleason Grading System and High-grade Tertiary Patterns to Grade Groups and Integrated Quantitative Gleason Score.
    Eur Urol. 2018;73:684-686.
    PubMed     Text format    


  299. KEARNS JT, Faino AV, Newcomb LF, Brooks JD, et al
    Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
    Eur Urol. 2018;73:706-712.
    PubMed     Text format     Abstract available


  300. THOMPSON JE, Egger S, Bohm M, Siriwardana AR, et al
    Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve-Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive Cases.
    Eur Urol. 2018;73:664-671.
    PubMed     Text format     Abstract available


  301. SAUTER G, Clauditz T, Steurer S, Wittmer C, et al
    Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens.
    Eur Urol. 2018;73:674-683.
    PubMed     Text format     Abstract available


    April 2018
  302. SANCHEZ-SALAS R, de la Rosette J, Polascik TJ, Carneiro A, et al
    Focal Therapy for Prostate Cancer: A More Vehement View of the Approach Could Translate into Real Benefits for Our Patients.
    Eur Urol. 2018 Apr 30. pii: S0302-2838(18)30320.
    PubMed     Text format     Abstract available


  303. ABDOLLAH F, Dalela D, Sood A, Keeley J, et al
    Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection.
    Eur Urol. 2018 Apr 29. pii: S0302-2838(18)30318.
    PubMed     Text format     Abstract available


  304. HEINRICH D, Russnes KM, Oldenburg J
    Re: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
    Eur Urol. 2018 Apr 21. pii: S0302-2838(18)30277.
    PubMed     Text format    


  305. TOUIJER K
    Reply to Pim J. van Leeuwen and Henk G. van der Poel's Letter to the Editor re: Karim A. Touijer, Robert J. Karnes, Niccolo Passoni, et al. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative An
    Eur Urol. 2018 Apr 21. pii: S0302-2838(18)30259.
    PubMed     Text format    


  306. WALZ J
    Re: Surveillance or Metastasis-directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
    Eur Urol. 2018 Apr 18. pii: S0302-2838(18)30255.
    PubMed     Text format    


  307. HAN S, Woo S, Kim YJ, Suh CH, et al
    Impact of (68)Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2018 Apr 17. pii: S0302-2838(18)30248.
    PubMed     Text format     Abstract available


  308. NUHN P, De Bono JS, Fizazi K, Freedland SJ, et al
    Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Eur Urol. 2018 Apr 16. pii: S0302-2838(18)30246.
    PubMed     Text format     Abstract available


  309. VAN LEEUWEN PJ, van der Poel HG
    Re: Karim A. Touijer, Robert Jeffery Karnes, Niccolo Passoni, et al. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Eur Urol. In p
    Eur Urol. 2018 Apr 13. pii: S0302-2838(18)30258.
    PubMed     Text format    


  310. VAN STAM MA, van der Poel H
    The New Standard: Personalised Information about the Risks and Benefits of Treatment Strategies for Localised Prostate Cancer.
    Eur Urol. 2018 Apr 13. pii: S0302-2838(18)30199.
    PubMed     Text format    


  311. REICHARD CA, Gregg JR, Achim MF, Aparicio AM, et al
    Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes.
    Eur Urol. 2018 Apr 12. pii: S0302-2838(18)30249.
    PubMed     Text format     Abstract available


  312. ALCARAZ A, Mengual L
    Re: Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
    Eur Urol. 2018 Apr 12. pii: S0302-2838(18)30256.
    PubMed     Text format    


  313. HAIDL F, Heidenreich A, Pfister D
    Re: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
    Eur Urol. 2018 Apr 10. pii: S0302-2838(18)30247.
    PubMed     Text format    


  314. VILLERS A, Olivier J
    Re: Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Eur Urol. 2018 Apr 9. pii: S0302-2838(18)30242.
    PubMed     Text format    


  315. GIANNARINI G, Fossati N, Gandaglia G, Cucchiara V, et al
    Will Image-guided Metastasis-directed Therapy Change the Treatment Paradigm of Oligorecurrent Prostate Cancer?
    Eur Urol. 2018 Apr 3. pii: S0302-2838(18)30202.
    PubMed     Text format    


  316. MAURER T, Robu S, Schottelius M, Schwamborn K, et al
    (99m)Technetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer.
    Eur Urol. 2018 Apr 3. pii: S0302-2838(18)30189.
    PubMed     Text format     Abstract available


  317. CARNEIRO A, Sanchez-Salas R
    Re: Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018.
    Eur Urol. 2018 Apr 3. pii: S0302-2838(18)30204.
    PubMed     Text format    


  318. KAMRAN SC, Seisen T, Markt SC, Preston MA, et al
    Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns' Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cance
    Eur Urol. 2018;73:e96-e97.
    PubMed     Text format    


  319. HAJDINJAK T, Pelzer AE
    Re: What Are We Missing? False-negative Cancers at Multiparametric MR Imaging of the Prostate.
    Eur Urol. 2018;73:637.
    PubMed     Text format    


  320. FRYDENBERG M, Woo HH
    Early Androgen Deprivation Therapy Improves Survival, But How Do We Determine in Whom?
    Eur Urol. 2018;73:519-520.
    PubMed     Text format    


  321. BRAND D, Parker C
    Management of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation.
    Eur Urol. 2018;73:521-523.
    PubMed     Text format     Abstract available


    March 2018
  322. LAVORGNA G, Montorsi F, Salonia A
    Re: Jinjing Chen, Ilaria Guccini, Diletta Di Mitri, et al. Compartmentalized Activities of the Pyruvate Dehydrogenase Complex Sustain Lipogenesis in Prostate Cancer. Nat Genet 2018;50:219-28: Lipid Metabolism in Prostate Cancer: Expanding Patient Ther
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30181.
    PubMed     Text format    


  323. EKLUND M, Strom P, Nordstrom T, Gronberg H, et al
    Reply to Ola Bratt and Anna Ofverholm's Letter to the Editor re: Peter Strom, Tobias Nordstrom, Henrik Gronberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. E
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30185.
    PubMed     Text format    


  324. TOSOIAN JJ, Lotan TL
    The Androgen Signaling Axis and Risk Stratification for High-grade Prostate Cancer.
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30188.
    PubMed     Text format    


  325. BRATT O, Ofverholm A
    Re: Peter Strom, Tobias Nordstrom, Henrik Gronberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.12.0
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30186.
    PubMed     Text format    


  326. KINSELLA N, Stattin P, Cahill D, Brown C, et al
    Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review.
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30176.
    PubMed     Text format     Abstract available


  327. VAN SOEST RJ, Tombal B, Lolkema MP, de Wit R, et al
    Cell-free DNA in Advanced Prostate Cancer: A Biomarker Revolution Under Way?
    Eur Urol. 2018 Mar 19. pii: S0302-2838(18)30178.
    PubMed     Text format    


  328. PANEBIANCO V, Barchetti G, Simone G, Del Monte M, et al
    Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
    Eur Urol. 2018 Mar 19. pii: S0302-2838(18)30183.
    PubMed     Text format     Abstract available


  329. HAO J, Ci X, Xue H, Wu R, et al
    Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Mar 12. pii: S0302-2838(18)30162.
    PubMed     Text format     Abstract available


  330. MONTGOMERY B, Lin DW
    Adjuvant Chemotherapy for Prostate Cancer: The Long and Winding Road.
    Eur Urol. 2018 Mar 8. pii: S0302-2838(18)30164.
    PubMed     Text format    


  331. DAVIS ID
    Answering Questions and Questioning Answers: More Evidence To Guide Decision-making About Chemohormonal Therapy in Metastatic Prostate Cancer.
    Eur Urol. 2018 Mar 7. pii: S0302-2838(18)30163.
    PubMed     Text format    


  332. SJOBERG DD, Vickers AJ, Assel M, Dahlin A, et al
    Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
    Eur Urol. 2018 Mar 5. pii: S0302-2838(18)30126.
    PubMed     Text format     Abstract available


    February 2018
  333. TYSON MD 2ND, Koyama T, Lee D, Hoffman KE, et al
    Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results.
    Eur Urol. 2018 Feb 28. pii: S0302-2838(18)30119.
    PubMed     Text format     Abstract available


  334. MEHRA N, Dolling D, Sumanasuriya S, Christova R, et al
    Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
    Eur Urol. 2018 Feb 27. pii: S0302-2838(18)30120.
    PubMed     Text format     Abstract available


  335. MAHAL BA, Yang DD, Wang NQ, Alshalalfa M, et al
    Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.
    Eur Urol. 2018 Feb 22. pii: S0302-2838(18)30098.
    PubMed     Text format     Abstract available


  336. GRAVIS G, Boher JM, Chen YH, Liu G, et al
    Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
    Eur Urol. 2018 Feb 20. pii: S0302-2838(18)30102.
    PubMed     Text format     Abstract available


  337. CHANDRASEKAR T, Ost P, Tilki D
    Is (68)Ga-Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography Ready To Simplify the Conundrum of Biochemically Recurrent Prostate Cancer?
    Eur Urol. 2018 Feb 19. pii: S0302-2838(18)30083.
    PubMed     Text format    


  338. FARIA R, Soares MO, Spackman E, Ahmed HU, et al
    Re: Jochen Walz. The "PROMIS" of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis? Eur Urol 2018;73:31-2.
    Eur Urol. 2018 Feb 17. pii: S0302-2838(18)30110.
    PubMed     Text format    


  339. AGGARWAL R
    Defining the Prognostic and Predictive Impact of Germline DNA Repair Mutations in Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Feb 16. pii: S0302-2838(18)30112.
    PubMed     Text format    


  340. LAMB AD, Bryant RJ, Mills IG, Hamdy FC, et al
    First Report of Prostate-specific Membrane Antigen-targeted Immunotherapy in Prostate Cancer: The Future is Bright.
    Eur Urol. 2018 Feb 16. pii: S0302-2838(18)30114.
    PubMed     Text format    


  341. MOROTE J, Comas I, Planas J
    Re: Nicolas Mottet, Joaquim Bellmunt, Erik Briers, et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2017. http://uroweb.org/guideline/prostate-cancer: How to Assess the Efficacy of Medical Castration.
    Eur Urol. 2018 Feb 13. pii: S0302-2838(18)30093.
    PubMed     Text format    


  342. HAESE A
    Re: Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
    Eur Urol. 2018 Feb 10. pii: S0302-2838(18)30086.
    PubMed     Text format    


  343. ANTONARAKIS ES, Lu C, Luber B, Liang C, et al
    Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Eur Urol. 2018 Feb 10. pii: S0302-2838(18)30089.
    PubMed     Text format     Abstract available


  344. COOPERBERG MR, Brooks JD, Faino AV, Newcomb LF, et al
    Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Eur Urol. 2018 Feb 9. pii: S0302-2838(18)30067.
    PubMed     Text format     Abstract available


  345. FAIENA I, Salmasi A, Pantuck AJ, Drakaki A, et al
    Re: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    Eur Urol. 2018 Feb 9. pii: S0302-2838(18)30077.
    PubMed     Text format    


  346. AMINSHARIFI A, Polascik TJ
    Re: Prevalence and Prognosis of Low-volume, Oligorecurrent, Hormone-sensitive Prostate Cancer Amenable to Lesion Ablative Therapy.
    Eur Urol. 2018 Feb 7. pii: S0302-2838(18)30076.
    PubMed     Text format    


  347. COOPERBERG MR
    How Should a Man with Prostate Cancer Choose his Surgeon?
    Eur Urol. 2018 Feb 3. pii: S0302-2838(18)30074.
    PubMed     Text format    


  348. WINTER A, Chavan A, Wawroschek F
    Magnetic Resonance Imaging of Sentinel Lymph Nodes Using Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer Patients: First-in-human Results.
    Eur Urol. 2018 Feb 2. pii: S0302-2838(18)30018.
    PubMed     Text format    


  349. TO SQ, Kwan EM, Fettke HC, Mant A, et al
    Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Feb 2. pii: S0302-2838(18)30016.
    PubMed     Text format     Abstract available


  350. PARKER C, Sydes MR
    Salvage Treatment After Radical Prostatectomy.
    Eur Urol. 2018;73:166-167.
    PubMed     Text format    


  351. CHIN JL
    Robotic-assisted Radical Prostatectomy for High-risk Cancer: Time for "Sexta-fecta".
    Eur Urol. 2018;73:224-225.
    PubMed     Text format    


  352. TILKI D, Evans CP
    The Decipher Genomic Classifier Independently Improves Prognostication for Patients After Prostatectomy.
    Eur Urol. 2018;73:176-177.
    PubMed     Text format    


  353. BRZEZNIAK C, Oronsky B, Aggarwal R
    A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets.
    Eur Urol. 2018;73:306-307.
    PubMed     Text format    


  354. HERLEMANN A, Cowan JE, Carroll PR, Cooperberg MR, et al
    Community-based Outcomes of Open versus Robot-assisted Radical Prostatectomy.
    Eur Urol. 2018;73:215-223.
    PubMed     Text format     Abstract available


    January 2018
  355. TEMIZ MZ, Besiroglu H
    Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur
    Eur Urol. 2018 Jan 31. pii: S0302-2838(18)30023.
    PubMed     Text format    


  356. KAPOOR DA
    Prostate Cancer Care and Practice Patterns: Low-quality Observations Miss the Benefits from High-quality Care.
    Eur Urol. 2018 Jan 30. pii: S0302-2838(18)30006.
    PubMed     Text format    


  357. MATEO J, Cheng HH, Beltran H, Dolling D, et al
    Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.
    Eur Urol. 2018 Jan 29. pii: S0302-2838(18)30019.
    PubMed     Text format     Abstract available


  358. AHLGREN GM, Flodgren P, Tammela TLJ, Kellokumpu-Lehtinen P, et al
    Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
    Eur Urol. 2018 Jan 27. pii: S0302-2838(18)30021.
    PubMed     Text format     Abstract available


  359. GANDAGLIA G, Fossati N, Montorsi F, Briganti A, et al
    Reply to Mustafa Z. Temiz and Huseyin Besiroglu's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical
    Eur Urol. 2018 Jan 27. pii: S0302-2838(18)30024.
    PubMed     Text format    


  360. RAUSCHER I, Duwel C, Haller B, Rischpler C, et al
    Efficacy, Predictive Factors, and Prediction Nomograms for (68)Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.
    Eur Urol. 2018 Jan 18. pii: S0302-2838(18)30010.
    PubMed     Text format     Abstract available


  361. VAN DER POEL HG, van den Bergh RCN, Briers E, Cornford P, et al
    Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018.
    Eur Urol. 2018 Jan 17. pii: S0302-2838(18)30005.
    PubMed     Text format     Abstract available


  362. STROM P, Nordstrom T, Gronberg H, Eklund M, et al
    The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
    Eur Urol. 2018 Jan 10. pii: S0302-2838(17)31096.
    PubMed     Text format     Abstract available


  363. UO T, Sprenger C
    Androgen Receptor Variants and Castration-resistant Prostate Cancer: Looking Back and Looking Forward.
    Eur Urol. 2018 Jan 3. pii: S0302-2838(17)31067.
    PubMed     Text format    


  364. LEE JK, Sjoberg DD, Miller MI, Vickers AJ, et al
    Improved Recovery of Erectile Function in Younger Men after Radical Prostatectomy: Does it Justify Immediate Surgery in Low-risk Patients?
    Eur Urol. 2018;73:33-37.
    PubMed     Text format     Abstract available


  365. CULIG Z
    Innovative Therapies to Overcome Resistance to Enzalutamide: Perspective on the Use of Darolutamide.
    Eur Urol. 2018;73:9-10.
    PubMed     Text format    


  366. LEE B, Kim JH
    Re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol 2017;72:402-7.
    Eur Urol. 2018;73:e13-e14.
    PubMed     Text format    


  367. UREN AD, Cotterill N, Harding C, Hillary C, et al
    Reply to Bora Lee and Jae Heon Kim's Letter to the Editor re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol 2017;72:402-7.
    Eur Urol. 2018;73:e15-e16.
    PubMed     Text format    


    December 2017
  368. BOSSI A
    Re: Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update.
    Eur Urol. 2017 Dec 26. pii: S0302-2838(17)31046.
    PubMed     Text format    


  369. FRASER M, Boutros PC, Bristow RG
    A Partner in Crime: Tumor-associated Stroma and Metastatic Prostate Cancer.
    Eur Urol. 2017 Dec 21. pii: S0302-2838(17)31021.
    PubMed     Text format    


  370. ROACH M RD
    Re: Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy Versus External Beam Radiation.
    Eur Urol. 2017 Dec 21. pii: S0302-2838(17)31041.
    PubMed     Text format    


  371. ZHANG Q, Helfand BT, Carneiro BA, Qin W, et al
    Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-beta Insensitive Genetically Targeted CD8(+) T-cells Derived from Patients with Metastatic Castrate-resistant Disease.
    Eur Urol. 2017 Dec 21. pii: S0302-2838(17)31040.
    PubMed     Text format     Abstract available


  372. ROCCO B, Eissa A, Bianchi G
    Re: Positron Emission Tomography/Computed Tomography-based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2017 Dec 20. pii: S0302-2838(17)31036.
    PubMed     Text format    


  373. OZEN H, Turkeri LN
    Re: Active Surveillance in Younger Men with Prostate Cancer.
    Eur Urol. 2017 Dec 19. pii: S0302-2838(17)31044.
    PubMed     Text format    


  374. LUO J, Attard G, Balk SP, Bevan C, et al
    Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.
    Eur Urol. 2017 Dec 16. pii: S0302-2838(17)31030.
    PubMed     Text format     Abstract available


  375. ROBINSON D, Garmo H, Lissbrant IF, Widmark A, et al
    Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study.
    Eur Urol. 2017 Dec 15. pii: S0302-2838(17)31031.
    PubMed     Text format     Abstract available


  376. SPRATT DE, Dai DLY, Den RB, Troncoso P, et al
    Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.
    Eur Urol. 2017 Dec 9. pii: S0302-2838(17)31016.
    PubMed     Text format     Abstract available


  377. VALE C, Fisher D, Tierney J, White I, et al
    Re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analy
    Eur Urol. 2017 Dec 9. pii: S0302-2838(17)31019.
    PubMed     Text format    


  378. WALLIS CJD, Klaassen Z
    Response to Claire Vale, David Fisher, Jayne Tierney, Ian White, Matthew Sydes, and James Carpenter's Letter to the Editor re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androge
    Eur Urol. 2017 Dec 7. pii: S0302-2838(17)31020.
    PubMed     Text format    


  379. DONG L, Pienta KJ
    Re: Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
    Eur Urol. 2017 Dec 5. pii: S0302-2838(17)31023.
    PubMed     Text format    


    November 2017
  380. HAMDY FC, Lamb AD, Bryant RJ
    Diagnostic Pathways for Screen-detected Prostate Cancer: The Plot Thickens.
    Eur Urol. 2017 Nov 28. pii: S0302-2838(17)30994.
    PubMed     Text format    


  381. COOPERBERG MR
    Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer.
    Eur Urol. 2017 Nov 28. pii: S0302-2838(17)30982.
    PubMed     Text format    


  382. ABDOLLAH F, Dalela D, Menon M
    Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer.
    Eur Urol. 2017 Nov 22. pii: S0302-2838(17)30985.
    PubMed     Text format    


  383. LOEB S
    Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer.
    Eur Urol. 2017 Nov 20. pii: S0302-2838(17)30976.
    PubMed     Text format    


  384. CRUMBAKER M, Savdie R, Joshua AM
    Refining the Assessment and Implications of AR-V7 in Castrate-resistant Prostate Cancer.
    Eur Urol. 2017 Nov 18. pii: S0302-2838(17)30981.
    PubMed     Text format    


  385. MARTINI A, Gupta A, Cumarasamy S, Tewari AK, et al
    Re: Rita Faria, Marta O. Soares, Eldon Spackman, et al. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). Eur Urol. In p
    Eur Urol. 2017 Nov 10. pii: S0302-2838(17)30974.
    PubMed     Text format    


  386. LAMB AD, Bryant RJ, Camilleri P, Hamdy FC, et al
    Orient Expression: Solving the Mystery of Asian Prostate Cancer?
    Eur Urol. 2017 Nov 10. pii: S0302-2838(17)30969.
    PubMed     Text format    


  387. LAVORGNA G, Montorsi F, Salonia A
    Re: Ken J. Kron, Alexander Murison, Stanley Zhou, et al. TMPRSS2-ERG Fusion Co-opts Master Transcription Factors and Activates NOTCH Signaling in Primary Prostate Cancer. Nat Genet 2017;49:1336-45.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30973.
    PubMed     Text format    


  388. CUCCHIARA V, Cooperberg MR, Dall'Era M, Lin DW, et al
    Genomic Markers in Prostate Cancer Decision Making.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30975.
    PubMed     Text format     Abstract available


  389. TOMBAL B
    Assembling the Puzzle of Advanced Prostate Cancer: Lessons from GETUG-AFU 15.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30968.
    PubMed     Text format    


  390. AGGARWAL R
    Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers.
    Eur Urol. 2017 Nov 8. pii: S0302-2838(17)30967.
    PubMed     Text format    


  391. RAMEY SJ, Agrawal S, Abramowitz MC, Moghanaki D, et al
    Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.
    Eur Urol. 2017 Nov 8. pii: S0302-2838(17)30900.
    PubMed     Text format     Abstract available


  392. CULINE S
    Customizing Daily Management of Castrate-resistant Prostate Cancer: Waiting for the Next Step.
    Eur Urol. 2017 Nov 6. pii: S0302-2838(17)30907.
    PubMed     Text format    


  393. IBRAGIMOVA N, Zhanzak Z, Meyerbekova A, Xie Y, et al
    Re: Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
    Eur Urol. 2017 Nov 4. pii: S0302-2838(17)30910.
    PubMed     Text format    


  394. MOTTET N, De Santis M, Briers E, Gillessen S, et al
    Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard.
    Eur Urol. 2017 Nov 2. pii: S0302-2838(17)30839.
    PubMed     Text format     Abstract available


    October 2017
  395. HEINZELBECKER J, Stockle M
    Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer.
    Eur Urol. 2017 Oct 30. pii: S0302-2838(17)30899.
    PubMed     Text format    


  396. SPRATT DE, Dess RT, Feng FY
    Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Can
    Eur Urol. 2017 Oct 27. pii: S0302-2838(17)30897.
    PubMed     Text format    


  397. LAVAUD P, Gravis G, Foulon S, Joly F, et al
    Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naive Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Eur Urol. 2017 Oct 23. pii: S0302-2838(17)30791.
    PubMed     Text format     Abstract available


  398. ASSEL M, Dahlin A, Ulmert D, Bergh A, et al
    Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
    Eur Urol. 2017 Oct 21. pii: S0302-2838(17)30860.
    PubMed     Text format     Abstract available


  399. SAITO K, Fujii Y
    Antitumor Activity and Safety of Enzalutamide After Abiraterone Acetate: Seeking the Optimal Treatment Sequence for Castration-resistant Prostate Cancer Patients.
    Eur Urol. 2017 Oct 20. pii: S0302-2838(17)30858.
    PubMed     Text format    


  400. GHADJAR P, Wiegel T
    Re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017
    Eur Urol. 2017 Oct 19. pii: S0302-2838(17)30861.
    PubMed     Text format    


  401. GOOD DW, McNeill AS
    Re: Impact of Radical Prostatectomy on Long-term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration.
    Eur Urol. 2017 Oct 17. pii: S0302-2838(17)30844.
    PubMed     Text format    


  402. VAN DER KWAST T
    Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient-specific Molds to Correlate Images with Whole-mount Pathology.
    Eur Urol. 2017 Oct 14. pii: S0302-2838(17)30842.
    PubMed     Text format    


  403. TOUIJER KA, Karnes RJ, Passoni N, Sjoberg DD, et al
    Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
    Eur Urol. 2017 Oct 14. pii: S0302-2838(17)30828.
    PubMed     Text format     Abstract available


  404. MCLEOD DG, Petrovics G
    Re: Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
    Eur Urol. 2017 Oct 13. pii: S0302-2838(17)30845.
    PubMed     Text format    


  405. WALLIS CJD, Klaassen Z, Bhindi B, Goldberg H, et al
    Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Eur Urol. 2017 Oct 13. pii: S0302-2838(17)30849.
    PubMed     Text format     Abstract available


  406. SPAHN M
    Re: Metastasis-free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
    Eur Urol. 2017 Oct 12. pii: S0302-2838(17)30843.
    PubMed     Text format    


  407. PLOUSSARD G
    Re: Salvage High-intensity Focused Ultrasound (HIFU) for Locally Recurrent Prostate Cancer After Failed Radiation Therapy: Multi-institutional Analysis of 418 Patients.
    Eur Urol. 2017 Oct 12. pii: S0302-2838(17)30841.
    PubMed     Text format    


  408. VAN DEN EEDEN SK, Lu R, Zhang N, Quesenberry CP Jr, et al
    A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Eur Urol. 2017 Oct 5. pii: S0302-2838(17)30777.
    PubMed     Text format     Abstract available


    September 2017
  409. WALZ J
    The "PROMIS" of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis?
    Eur Urol. 2017 Sep 28. pii: S0302-2838(17)30779.
    PubMed     Text format    


  410. PANSADORO V, Brassetti A
    Re: Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer.
    Eur Urol. 2017 Sep 25. pii: S0302-2838(17)30782.
    PubMed     Text format    


  411. CAPOGROSSO P, Montorsi F
    Erectile Function Recovery After Surgery in Young Men with Low-risk Prostate Cancer: Probably Not Just a Matter of Age, Certainly Not the Main Point of Discussion.
    Eur Urol. 2017 Sep 25. pii: S0302-2838(17)30726.
    PubMed     Text format    


  412. GASSER T
    Re: Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-term Oncologic Outcomes in a Shared Equal-access Health System.
    Eur Urol. 2017 Sep 20. pii: S0302-2838(17)30727.
    PubMed     Text format    


  413. MILLER K, Carles J, Gschwend JE, Van Poppel H, et al
    The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
    Eur Urol. 2017 Sep 19. pii: S0302-2838(17)30728.
    PubMed     Text format     Abstract available


  414. FARIA R, Soares MO, Spackman E, Ahmed HU, et al
    Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).
    Eur Urol. 2017 Sep 18. pii: S0302-2838(17)30711.
    PubMed     Text format     Abstract available


  415. REN S, Wei GH, Liu D, Wang L, et al
    Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression.
    Eur Urol. 2017 Sep 15. pii: S0302-2838(17)30720.
    PubMed     Text format     Abstract available


  416. GANDAGLIA G, Fossati N, Montorsi F, Briganti A, et al
    Reply to Alan Dal Pra, Stephane Supiot and Pirus Ghadjar's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen Afte
    Eur Urol. 2017 Sep 7. pii: S0302-2838(17)30719.
    PubMed     Text format    


  417. SEISEN T, Vetterlein MW, Karabon P, Jindal T, et al
    Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis.
    Eur Urol. 2017 Sep 7. pii: S0302-2838(17)30697.
    PubMed     Text format     Abstract available


  418. DAL PRA A, Supiot S, Ghadjar P
    Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur
    Eur Urol. 2017 Sep 7. pii: S0302-2838(17)30718.
    PubMed     Text format    


    August 2017
  419. ZHU Y, Sharp A, Anderson CM, Silberstein JL, et al
    Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2017 Aug 30. pii: S0302-2838(17)30695.
    PubMed     Text format     Abstract available


  420. GILLESSEN S, de Bono JS, Sartor O, Omlin AG, et al
    Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer
    Eur Urol. 2017 Aug 28. pii: S0302-2838(17)30700.
    PubMed     Text format    


  421. VON EYBEN FE, Virgolini I, Roviello G
    Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.
    Eur Urol. 2017 Aug 28. pii: S0302-2838(17)30696.
    PubMed     Text format    


  422. EGGER SJ, Calopedos RJ, O'Connell DL, Chambers SK, et al
    Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
    Eur Urol. 2017 Aug 26. pii: S0302-2838(17)30699.
    PubMed     Text format     Abstract available


  423. TAKEDA T, Tin AL, Corradi RB, Mamoor M, et al
    Topography of Prostate Cancer Recurrence After Radiation Therapy: A Detailed Mapping Study of Salvage Radical Prostatectomy Specimens.
    Eur Urol. 2017 Aug 26. pii: S0302-2838(17)30691.
    PubMed     Text format     Abstract available


  424. BORGMANN H, Lallous N, Ozistanbullu D, Beraldi E, et al
    Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Eur Urol. 2017 Aug 26. pii: S0302-2838(17)30698.
    PubMed     Text format     Abstract available


  425. DE BONO JS, Chowdhury S, Feyerabend S, Elliott T, et al
    Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for >/=24 weeks in Europe.
    Eur Urol. 2017 Aug 22. pii: S0302-2838(17)30664.
    PubMed     Text format     Abstract available


  426. LOEB S, Zhou Q, Siebert U, Rochau U, et al
    Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
    Eur Urol. 2017 Aug 22. pii: S0302-2838(17)30642.
    PubMed     Text format     Abstract available


  427. HOLLENBECK BK, Kaufman SR, Yan P, Herrel LA, et al
    Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly.
    Eur Urol. 2017 Aug 17. pii: S0302-2838(17)30687.
    PubMed     Text format     Abstract available


  428. SEITZ AK, Thoene S, Bietenbeck A, Nawroth R, et al
    AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Eur Urol. 2017 Aug 14. pii: S0302-2838(17)30653.
    PubMed     Text format     Abstract available


  429. WOO S, Suh CH, Kim SY
    Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cance
    Eur Urol. 2017 Aug 11. pii: S0302-2838(17)30669.
    PubMed     Text format    


  430. DEL RE M, Biasco E, Crucitta S, Derosa L, et al
    Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resi
    Eur Urol. 2017 Aug 8. pii: S0302-2838(17)30663.
    PubMed     Text format    


  431. MESSINA C, Messina M, Boccardo F
    Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
    Eur Urol. 2017 Aug 8. pii: S0302-2838(17)30659.
    PubMed     Text format    


  432. AYUBI E, Safiri S
    Re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis. Eur Urol
    Eur Urol. 2017 Aug 8. pii: S0302-2838(17)30668.
    PubMed     Text format    


  433. DE GIORGI U, Conteduca V, Scarpi E
    Re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680
    Eur Urol. 2017 Aug 5. pii: S0302-2838(17)30661.
    PubMed     Text format    


  434. KLEIN EA
    Reply to Parham Habibzadeh and Farrokh Habibzadeh's Letter to the Editor re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate
    Eur Urol. 2017 Aug 5. pii: S0302-2838(17)30644.
    PubMed     Text format    


  435. DOWNER MK
    Why Epidemiological Studies of Physical Activity in Prostate Cancer Often Underestimate its Benefits.
    Eur Urol. 2017 Aug 3. pii: S0302-2838(17)30656.
    PubMed     Text format    


  436. FRIEDLANDER DF, Trinh QD, Krasnova A, Lipsitz SR, et al
    Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics.
    Eur Urol. 2017 Aug 1. pii: S0302-2838(17)30652.
    PubMed     Text format     Abstract available


    July 2017
  437. AGGARWAL R, Vigneron DB, Kurhanewicz J
    Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer.
    Eur Urol. 2017 Jul 29. pii: S0302-2838(17)30651.
    PubMed     Text format    


  438. AGGARWAL A, Lewis D, Charman SC, Mason M, et al
    Determinants of Patient Mobility for Prostate Cancer Surgery: A Population-based Study of Choice and Competition.
    Eur Urol. 2017 Jul 28. pii: S0302-2838(17)30601.
    PubMed     Text format     Abstract available


  439. LARDAS M, Liew M, van den Bergh RC, De Santis M, et al
    Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review.
    Eur Urol. 2017 Jul 27. pii: S0302-2838(17)30535.
    PubMed     Text format     Abstract available


  440. TREE A, Dearnaley D
    Randomised Controlled Trials Remain the Key to Progress in Localised Prostate Cancer.
    Eur Urol. 2017 Jul 21. pii: S0302-2838(17)30590.
    PubMed     Text format    


  441. CROOK J
    Optimal Radiotherapy for Unfavorable-risk Prostate Cancer.
    Eur Urol. 2017 Jul 21. pii: S0302-2838(17)30589.
    PubMed     Text format    


  442. PENSON DF
    Quality of Life Outcomes Following Treatment for Localized Prostate Cancer: What's New and What's Not.
    Eur Urol. 2017 Jul 20. pii: S0302-2838(17)30588.
    PubMed     Text format    


  443. CARAM MEV, Miller DC
    Treating Advanced Prostate Cancer-the Human Factor.
    Eur Urol. 2017 Jul 18. pii: S0302-2838(17)30585.
    PubMed     Text format    


  444. SPRATT DE, Dess RT, Zumsteg ZS, Lin DW, et al
    A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer.
    Eur Urol. 2017 Jul 14. pii: S0302-2838(17)30527.
    PubMed     Text format     Abstract available


  445. WANG Y, Jacobs EJ, Gapstur SM, Maliniak ML, et al
    Recreational Physical Activity in Relation to Prostate Cancer-specific Mortality Among Men with Nonmetastatic Prostate Cancer.
    Eur Urol. 2017 Jul 12. pii: S0302-2838(17)30537.
    PubMed     Text format     Abstract available


  446. PARKER CC, Coleman RE, Sartor O, Vogelzang NJ, et al
    Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.
    Eur Urol. 2017 Jul 10. pii: S0302-2838(17)30516.
    PubMed     Text format     Abstract available


  447. LUO J, Luber B, Wang H, Antonarakis ES, et al
    Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz's Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection
    Eur Urol. 2017 Jul 7. pii: S0302-2838(17)30532.
    PubMed     Text format    


  448. GALFANO A, Secco S, Bocciardi AM
    Will Retzius-sparing Prostatectomy Be the Future of Prostate Cancer Surgery?
    Eur Urol. 2017 Jul 7. pii: S0302-2838(17)30523.
    PubMed     Text format    


  449. KIM JH, Lee B, Chung BI
    Re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. ht
    Eur Urol. 2017 Jul 6. pii: S0302-2838(17)30524.
    PubMed     Text format    


  450. STEINESTEL J, Bernemann C, Schrader AJ, Lennerz JK, et al
    Re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and S
    Eur Urol. 2017 Jul 5. pii: S0302-2838(17)30531.
    PubMed     Text format    


  451. JOHNSON SB, Lester-Coll NH, Kelly JR, Kann BH, et al
    Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
    Eur Urol. 2017 Jul 5. pii: S0302-2838(17)30515.
    PubMed     Text format     Abstract available


  452. WOO S, Suh CH, Kim SY
    Reply to Jae Heon Kim, Bora Lee, and Benjamin I. Chung's Letter to the Editor re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in
    Eur Urol. 2017 Jul 5. pii: S0302-2838(17)30525.
    PubMed     Text format    


  453. HABIBZADEH P, Habibzadeh F
    Re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based
    Eur Urol. 2017 Jul 4. pii: S0302-2838(17)30528.
    PubMed     Text format    


    June 2017
  454. GILLESSEN S, Attard G, Beer TM, Beltran H, et al
    Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
    Eur Urol. 2017 Jun 24. pii: S0302-2838(17)30497.
    PubMed     Text format     Abstract available


  455. ALBERTS AR, Schoots IG, Bokhorst LP, Drost FH, et al
    Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic R
    Eur Urol. 2017 Jun 21. pii: S0302-2838(17)30514.
    PubMed     Text format     Abstract available


  456. D'ANDREA D, Shariat SF
    Re: Radiation with or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Eur Urol. 2017 Jun 20. pii: S0302-2838(17)30513.
    PubMed     Text format    


  457. THYSELL E, Ylitalo EB, Jernberg E, Bergh A, et al
    Reply to Isabel Heidegger, Renate Pichler, and Andreas Pircher's Letter to the Editor re: Erik Bovinder Ylitalo, Elin Thysell, Emma Jernberg, et al. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relations
    Eur Urol. 2017 Jun 19. pii: S0302-2838(17)30504.
    PubMed     Text format    


  458. TREE AC, Siva S, Ost P
    Re: Declan G. Murphy, Christopher J. Sweeney, Bertrand Tombal. "Gotta Catch 'em All" or Do We? Pokemet Approach to Metastatic Prostate Cancer. Eur Urol 2017;72:1-3.
    Eur Urol. 2017 Jun 19. pii: S0302-2838(17)30506.
    PubMed     Text format    


  459. GANDAGLIA G, Boorjian SA, Parker WP, Zaffuto E, et al
    Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
    Eur Urol. 2017 Jun 13. pii: S0302-2838(17)30496.
    PubMed     Text format     Abstract available


  460. WALLIS CJD, Glaser A, Hu JC, Huland H, et al
    Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review.
    Eur Urol. 2017 Jun 10. pii: S0302-2838(17)30495.
    PubMed     Text format     Abstract available


  461. HOYLE AP, Clarke NW
    Magnetic Resonance Imaging and Detection of Metastases in Prostate Cancer: Learning Lessons from History.
    Eur Urol. 2017 Jun 8. pii: S0302-2838(17)30492.
    PubMed     Text format    


  462. ALBERTSEN PC
    Re: 10-Year Outcomes After Monitoring, Surgery or Radiotherapy for Localized Prostate Cancer.
    Eur Urol. 2017 Jun 8. pii: S0302-2838(17)30485.
    PubMed     Text format    


  463. HEIDEGGER I, Pichler R, Pircher A
    Re: Erik Bovinder Ylitalo, Elin Thysell, Emma Jernberg, et al. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response. Eur Urol 2017;71:776-87.
    Eur Urol. 2017 Jun 8. pii: S0302-2838(17)30493.
    PubMed     Text format    


  464. CLARKE NW
    Re: Nicola Fossati, Peter-Paul M. Willemse, Thomas Van den Broeck, et al. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol. In Press. http://dx.doi.org
    Eur Urol. 2017 Jun 1. pii: S0302-2838(17)30410.
    PubMed     Text format    


  465. MANDEL P, Preisser F, Graefen M, Steuber T, et al
    High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy.
    Eur Urol. 2017;71:848-850.
    PubMed     Text format     Abstract available


  466. HEESAKKERS J, Farag F, Bauer RM, Sandhu J, et al
    Pathophysiology and Contributing Factors in Postprostatectomy Incontinence: A Review.
    Eur Urol. 2017;71:936-944.
    PubMed     Text format     Abstract available


    May 2017
  467. TROCK BJ, Karnes RJ
    Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
    Eur Urol. 2017 May 31. pii: S0302-2838(17)30464.
    PubMed     Text format    


  468. AYUBI E, Safiri S
    Re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.
    Eur Urol. 2017 May 30. pii: S0302-2838(17)30465.
    PubMed     Text format    


  469. WOO S, Suh CH, Kim SY
    Reply to Thorsten Derlin, Christoph-A. von Klot, and Katja Hueper's Letter to the Editor re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Met
    Eur Urol. 2017 May 30. pii: S0302-2838(17)30470.
    PubMed     Text format    


  470. WILT TJ, Dahm P
    Value of Prostate Cancer Care: New Information on New Therapies Suggest Less is More.
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30451.
    PubMed     Text format    


  471. DERLIN T, von Klot CA, Hueper K
    Re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. ht
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30469.
    PubMed     Text format    


  472. REICHARD CA, Chapin BF
    Local Therapy for Disseminated Prostate Cancer: Improved Outcomes or Biased Confounders?
    Eur Urol. 2017 May 25. pii: S0302-2838(17)30404.
    PubMed     Text format    


  473. WILT TJ, Dahm P
    Value of Prostate Cancer Care: New Information on New Therapies Suggest Less is More.
    Eur Urol. 2017 May 20. pii: S0302-2838(17)30402.
    PubMed     Text format    


  474. COOPERBERG MR
    The New US Preventive Services Task Force "C" Draft Recommendation for Prostate Cancer Screening.
    Eur Urol. 2017 May 20. pii: S0302-2838(17)30401.
    PubMed     Text format     Abstract available


  475. WANG R, Sun Y, Li L, Niu Y, et al
    Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9(R) to Suppress Enzalutamide-resistant Prostate Cancer Progression.
    Eur Urol. 2017 May 18. pii: S0302-2838(17)30285.
    PubMed     Text format     Abstract available


  476. NGUYEN PL, Haddad Z, Ross AE, Martin NE, et al
    Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
    Eur Urol. 2017 May 18. pii: S0302-2838(17)30390.
    PubMed     Text format     Abstract available


  477. HERMANNS T, Poyet C
    The Next Generation of Prostate Cancer Risk Calculators.
    Eur Urol. 2017 May 15. pii: S0302-2838(17)30387.
    PubMed     Text format    


  478. BECK M, Hayoz S, Ghadjar P
    Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Eur Urol. 2017 May 15. pii: S0302-2838(17)30385.
    PubMed     Text format    


  479. HADASCHIK B, Herrmann K
    Re: Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT Before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
    Eur Urol. 2017 May 15. pii: S0302-2838(17)30388.
    PubMed     Text format    


  480. CHUA MLK, Lo W, Pintilie M, Murgic J, et al
    A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
    Eur Urol. 2017 May 13. pii: S0302-2838(17)30344.
    PubMed     Text format     Abstract available


  481. MITRAKAS L
    Re: Pascal Rischmann, Albert Gelet, Benjamin Riche, et al. Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate cancer: A Prospective Multicentric Hemiablation Study of 111 Patients. Eur Urol 2017;71:267-73.
    Eur Urol. 2017 May 10. pii: S0302-2838(17)30345.
    PubMed     Text format    


  482. MIRTTI T, Aittokallio T
    Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40.
    Eur Urol. 2017 May 9. pii: S0302-2838(17)30340.
    PubMed     Text format    


  483. SEYEDNASROLLAH F, Mahmoudian M, Rautakorpi L, Hirvonen O, et al
    Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prost
    Eur Urol. 2017 May 9. pii: S0302-2838(17)30341.
    PubMed     Text format    


  484. LEAPMAN MS, Cowan JE, Simko J, Roberge G, et al
    Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes.
    Eur Urol. 2017;71:750-759.
    PubMed     Text format     Abstract available


  485. HE J, Albertsen PC, Moore D, Rotter D, et al
    Validation of a Contemporary Five-tiered Gleason Grade Grouping Using Population-based Data.
    Eur Urol. 2017;71:760-763.
    PubMed     Text format     Abstract available


  486. FROEHNER M, Koch R, Hubler M, Zastrow S, et al
    Predicting Competing Mortality in Patients Undergoing Radical Prostatectomy Aged 70 yr or Older.
    Eur Urol. 2017;71:710-713.
    PubMed     Text format     Abstract available


  487. BRAJTBORD JS, Leapman MS, Cooperberg MR
    The CAPRA Score at 10 Years: Contemporary Perspectives and Analysis of Supporting Studies.
    Eur Urol. 2017;71:705-709.
    PubMed     Text format     Abstract available


  488. TOSOIAN JJ, Almutairi F, Morais CL, Glavaris S, et al
    Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.
    Eur Urol. 2017;71:697-700.
    PubMed     Text format     Abstract available


  489. KISHAN AU, Shaikh T, Wang PC, Reiter RE, et al
    Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.
    Eur Urol. 2017;71:766-773.
    PubMed     Text format     Abstract available


  490. STUDENT V JR, Vidlar A, Grepl M, Hartmann I, et al
    Advanced Reconstruction of Vesicourethral Support (ARVUS) during Robot-assisted Radical Prostatectomy: One-year Functional Outcomes in a Two-group Randomised Controlled Trial.
    Eur Urol. 2017;71:822-830.
    PubMed     Text format     Abstract available


    April 2017
  491. YANG JC, Evans CP
    Adjunct Screening of NKX3.1 Expression Supports 5alpha-Reductase Inhibition Intervention in Prostate Cancer Active Surveillance.
    Eur Urol. 2017 Apr 25. pii: S0302-2838(17)30327.
    PubMed     Text format    


  492. PATEL DN, Freedland SJ
    New Prostate Cancer Biomarkers: The Search Continues.
    Eur Urol. 2017 Apr 24. pii: S0302-2838(17)30293.
    PubMed     Text format    


  493. WALSH PC
    The Search for the Missing Heritability of Prostate Cancer.
    Eur Urol. 2017 Apr 22. pii: S0302-2838(17)30283.
    PubMed     Text format     Abstract available


  494. GRUMMET JP, Plass K, N'Dow J
    Prostate Cancer Management in an Ageing Population.
    Eur Urol. 2017 Apr 19. pii: S0302-2838(17)30290.
    PubMed     Text format    


  495. SOORIAKUMARAN P, Nyberg T, Akre O, Widmark A, et al
    Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy.
    Eur Urol. 2017 Apr 14. pii: S0302-2838(17)30282.
    PubMed     Text format     Abstract available


  496. SOOD A, Abdollah F
    Re: Diagnostic Accuracy of Multi-parametric Magnetic Resonance Imaging and Transrectal Ultrasound Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study.
    Eur Urol. 2017 Apr 12. pii: S0302-2838(17)30275.
    PubMed     Text format    


  497. WOO S, Suh CH, Kim SY, Cho JY, et al
    Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2017 Apr 12. pii: S0302-2838(17)30273.
    PubMed     Text format     Abstract available


  498. GANDAGLIA G, Fossati N, Zaffuto E, Bandini M, et al
    Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.
    Eur Urol. 2017 Apr 12. pii: S0302-2838(17)30280.
    PubMed     Text format     Abstract available


  499. WALKER SM, Knight LA, McCavigan AM, Logan GE, et al
    Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.
    Eur Urol. 2017 Apr 10. pii: S0302-2838(17)30238.
    PubMed     Text format     Abstract available


  500. RADTKE JP, Wiesenfarth M, Kesch C, Freitag MT, et al
    Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Eur Urol. 2017 Apr 8. pii: S0302-2838(17)30267.
    PubMed     Text format     Abstract available


  501. KARNES RJ, Choeurng V, Ross AE, Schaeffer EM, et al
    Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
    Eur Urol. 2017 Apr 8. pii: S0302-2838(17)30264.
    PubMed     Text format     Abstract available


  502. KLEIN EA, Chait A, Hafron JM, Kernen KM, et al
    The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary
    Eur Urol. 2017 Apr 7. pii: S0302-2838(17)30236.
    PubMed     Text format     Abstract available



  503. Prostate Cancer and the John West Effect.
    Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30095.
    PubMed     Text format     Abstract available


  504. LEYH-BANNURAH SR, Gazdovich S, Budaus L, Zaffuto E, et al
    Local Therapy Improves Survival in Metastatic Prostate Cancer.
    Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30231.
    PubMed     Text format     Abstract available


  505. DUTTA A, Panja S, Virk RK, Kim JY, et al
    Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5alpha-reductase Inhibition.
    Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30252.
    PubMed     Text format     Abstract available


  506. WEGELIN O, van Melick HHE, Hooft L, Bosch JLHR, et al
    Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Techniqu
    Eur Urol. 2017;71:517-531.
    PubMed     Text format     Abstract available


    March 2017
  507. SCHROECK FR, Jacobs BL, Bhayani SB, Nguyen PL, et al
    Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.
    Eur Urol. 2017 Mar 30. pii: S0302-2838(17)30239.
    PubMed     Text format     Abstract available


  508. KIM JH, Khandwala YS, Chung BI
    Re: Jim C. Hu, David M. Nanus, Art Sedrakyan. Increase in prostate cancer metastases at radical prostatectomy in the United States. Eur Urol 2017;71:147-9.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30234.
    PubMed     Text format    


  509. SCHWEIZER MT, Antonarakis ES, Denmeade SR
    Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30233.
    PubMed     Text format     Abstract available


  510. PORTER LH, Lawrence MG, Ilic D, Clouston D, et al
    Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories.
    Eur Urol. 2017 Mar 22. pii: S0302-2838(17)30178.
    PubMed     Text format     Abstract available


  511. LAMB BW, Violet J, Siva S, Murphy DG, et al
    Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Eur Urol. 2017 Mar 20. pii: S0302-2838(17)30179.
    PubMed     Text format    


  512. MOLDOVAN PC, Van den Broeck T, Sylvester R, Marconi L, et al
    What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
    Eur Urol. 2017 Mar 20. pii: S0302-2838(17)30115.
    PubMed     Text format     Abstract available


  513. MO F, Lin D, Takhar M, Ramnarine VR, et al
    Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
    Eur Urol. 2017 Mar 19. pii: S0302-2838(17)30166.
    PubMed     Text format     Abstract available


  514. ALONGI F, Aiello D, Mazzola R, Cavalleri S, et al
    Re: Giorgio Gandaglia, Alberto Briganti, Noel Clarke, et al. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.01.039.
    Eur Urol. 2017 Mar 15. pii: S0302-2838(17)30169.
    PubMed     Text format    


  515. MOSCHINI M, Carroll PR, Eggener SE, Epstein JI, et al
    Low-risk Prostate Cancer: Identification, Management, and Outcomes.
    Eur Urol. 2017 Mar 15. pii: S0302-2838(17)30174.
    PubMed     Text format     Abstract available


  516. SMITH MR, Saad F, Rathkopf DE, Mulders PF, et al
    Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    Eur Urol. 2017 Mar 14. pii: S0302-2838(17)30172.
    PubMed     Text format     Abstract available


  517. ANTONARAKIS ES
    Germline DNA Repair Mutations and Response to Hormonal Therapy in Advanced Prostate Cancer.
    Eur Urol. 2017 Mar 14. pii: S0302-2838(17)30167.
    PubMed     Text format    


  518. DY GW, Gore JL, Forouzanfar MH, Naghavi M, et al
    Global Burden of Urologic Cancers, 1990-2013.
    Eur Urol. 2017;71:437-446.
    PubMed     Text format     Abstract available


  519. ADAM M, Tennstedt P, Lanwehr D, Tilki D, et al
    Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy.
    Eur Urol. 2017;71:330-336.
    PubMed     Text format     Abstract available


  520. FOSSATI N, Wiklund P, Rochat CH, Montorsi F, et al
    Robotic and Open Radical Prostatectomy: The First Prospective Randomised Controlled Trial Fuels Debate Rather than Closing the Question.
    Eur Urol. 2017;71:307-308.
    PubMed     Text format     Abstract available


  521. DASKIVICH TJ, Spiegel B, Kim HL
    Online Ratings Systems for Physicians and Institutions: Limitations of the Current State of the Art.
    Eur Urol. 2017;71:311-312.
    PubMed     Text format     Abstract available


  522. BORGHESI M, Ahmed H, Nam R, Schaeffer E, et al
    Complications After Systematic, Random, and Image-guided Prostate Biopsy.
    Eur Urol. 2017;71:353-365.
    PubMed     Text format     Abstract available


  523. MUNGOVAN SF, Sandhu JS, Akin O, Smart NA, et al
    Preoperative Membranous Urethral Length Measurement and Continence Recovery Following Radical Prostatectomy: A Systematic Review and Meta-analysis.
    Eur Urol. 2017;71:368-378.
    PubMed     Text format     Abstract available


    February 2017
  524. GRANDE P, Di Pierro GB, Mordasini L, Ferrari M, et al
    Prospective Randomized Trial Comparing Titanium Clips to Bipolar Coagulation in Sealing Lymphatic Vessels During Pelvic Lymph Node Dissection at the Time of Robot-assisted Radical Prostatectomy.
    Eur Urol. 2017;71:155-158.
    PubMed     Text format     Abstract available


  525. MA TM, Tosoian JJ, Schaeffer EM, Landis P, et al
    The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance.
    Eur Urol. 2017;71:174-180.
    PubMed     Text format     Abstract available


  526. ALBERS P
    Re: Reevaluating PSA Testing Rates in the PLCO Trial.
    Eur Urol. 2017;71:300.
    PubMed     Text format    


  527. DAMSGAARD J, Joensen UN, Carlsen E, Erenpreiss J, et al
    Reply to Eugenio Ventimiglia, Francesco Montorsi, and Andrea Salonia's Letter to the Editor re: Jakob Damsgaard, Ulla N. Joensen, Elisabeth Carlsen, et al. Varicocele Is Associated with Impaired Semen Quality and Reproductive Hormone Levels: A Study o
    Eur Urol. 2017;71:e71-e72.
    PubMed     Text format    


  528. STOLZENBURG JU, Kyriazis I, Liatsikos E
    Postoperative Lymphocele Formation after Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy Should Not Be Considered an Inevitable Consequence of the Approach.
    Eur Urol. 2017;71:159-160.
    PubMed     Text format    


  529. PRADO K, Reiter RE
    Is Targeted Biopsy Applicable to Patients on Active Surveillance?
    Eur Urol. 2017;71:181-182.
    PubMed     Text format    


    January 2017
  530. VALERIO M, Cerantola Y, Eggener SE, Lepor H, et al
    New and Established Technology in Focal Ablation of the Prostate: A Systematic Review.
    Eur Urol. 2017;71:17-34.
    PubMed     Text format     Abstract available


  531. SPRATT DE, Vargas HA, Zumsteg ZS, Golia Pernicka JS, et al
    Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage.
    Eur Urol. 2017;71:37-43.
    PubMed     Text format     Abstract available


  532. NICITA G, Villari D, Caroassai Grisanti S, Marzocco M, et al
    Minimally Invasive Transanal Repair of Rectourethral Fistulas.
    Eur Urol. 2017;71:133-138.
    PubMed     Text format     Abstract available


  533. LI Y, Donmez N, Sahinalp C, Xie N, et al
    SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
    Eur Urol. 2017;71:68-78.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: